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ABSTRACT 
 
Severe burn injury is one of the most devastating traumas with its direct tissue 
destruction, triggering a systemic inflammation and numerous cytokine-mediated 
alterations of homeostasis. Acute kidney injury (AKI) is a common sequela in severe 
burns and substantially increases the risk of death. Known risk factors for the 
development of AKI are the size of the burn area, age, simultaneous inhalation injury, 
sepsis and use of nephrotoxic antibiotics. Early AKI develops often from a lack of 
sufficient kidney perfusion due to insufficient circulation or from rhabdomyolysis. Late 
onset AKI is often part of multiple organ failure (MOF), which is a gradually 
progressing, poorly manageable state. MOF is characterized by abruption in 
coagulation, oxygenation of lungs and kidney function. The focus of this thesis was 
to investigate novel biomarkers of AKI: neutrophil gelatinase-associated lipocalin 
(NGAL) (I) and N-terminal pro-brain natriuretic peptide (NT-proBNP) (II) in primary 
diagnostics of AKI. The thesis also investigated the risk factors for AKI development 
after severe burn injury and factors affecting the outcome (III), as well the need for 
long-term renal replacement therapy (RRT) after severe burn injury and possible 
association of burn injury and cause of death (COD) (IV).  
 
Studies I and II enrolled 19 consecutive patients treated at Helsinki Burn Centre 
between March 2013 and September 2014. Plasma NGAL levels elevated over time 
in the majority of patients. Out of 19 patients, 17 showed elevated plasma NGAL 
levels (>150 ng/ml). Two patients showed high NGAL levels (>600ng/ml) without AKI. 
The area under the curve (AUC) was 0.62 in predicting AKI during the first week after 
a burn injury, whereas serum creatinine (SCr) and cystatin C (CysC) showed notably 
better diagnostic accuracy. A multivariable regression model showed that the NT-
proBNP was correlated with the volume of infused fluids and age but found a negative 
correlation between the body mass index (BMI) and NT-proBNP levels. NT-proBNP 
increased over time in all patients. The variation between patients was substantial, 
and even more variation was observed in patients who developed AKI. No 
association between AKI and high NT-proBNP was discovered.  
 
Study III found that 27.3% of patients developed AKI during the intensive care unit 
(ICU) stay, defined by an absolute SCr value of at least 120 μmol/l (1.4 mg/dl). 11.2% 
required RRT, and 19.8% of patients succumbed during their hospital stay. AKI 
patients showed 52.9% mortality compared to 7.4% of non-AKI patients. Age, 
TBSA%, sepsis and rhabdomyolysis were independent risk factors for AKI. The RRT 
had no effect on the significantly reduced mortality in AKI patients. AKI was 
associated with increased mortality, even in minor burns, and mortality increased 
substantially in major burns. The prognosis of major burns was relatively good 
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without AKI, though the majority of patients developed AKI in major burns (>50% 
burned TBSA). Age, TBSA%, sepsis and rhabdomyolysis were independent risk 
factors for AKI. Age, TBSA% and AKI were risk factors for death during an ICU stay. 
AKI substantially increased the risk of death (OR of 5.97, 95% CI 2.2-16.2). 
 
Study IV included 68 burn patients who had received RRT in the Helsinki Burn Centre 
between November 1988 and December 2015. 52.9% of patients succumbed during 
their hospital stay, and 32 discharged patients remained for follow-up. The need for 
RRT subsided before discharge in 81.3% of survivors. 6.3% of survivors needed RRT 
for over three months. Two patients received RRT constantly for a total of 10.5 and 
17 months, respectively. The need for RRT subsided over time in both cases. 35.7% 
of deaths occurred because of burns, 7.1% because of kidney failure and 57.1% of 
deaths occurred for any other reason. One patient developed chronic kidney disease 
(CKD) and succumbed during follow-up. The study showed CKD as a rare event after 
burn injury and RRT. It remains possible, however, that a prior burn injury may 
potentially enhance future development of AKI due to other reasons.  
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TIIVISTELMÄ  
 
Palovamma on yksi vakavimpia tapaturmia, jolle on ominaista suora kudostuho ja 
sen käynnistämä yleinen tulehdusreaktio ja välittäjäaineiden aiheuttama elimistön 
tasapainon järkkyminen. Akuutti munuaisvaurio on yleinen vaikeiden palovammojen 
seuraus ja se lisää tuntuvasti kuolleisuutta. Korkea ikä, palovamman laajuus, 
hengitystiepalovamma, verenmyrkytys ja munuaistoksisten antibioottien käyttö ovat 
munuaisvaurion tunnettuja riskitekijöitä. Varhainen akuutti munuaisvaurio syntyy 
useimmiten verenkiertovajauksesta johtuvasta munuaisten riittämättömästä 
hapensaannista tai rabdomyolyysistä, kun taas myöhäinen akuutti munuaisvaurio on 
usein osana monielinvauriota, jolle on ominaista etenevä häiriötila veren 
hyytymisessä, keuhkojen hapetuskyvyssä ja munuaisten toiminnassa ja tila on usein 
vaikeasti hallittavissa. Tämän tutkimuksen tarkoituksena oli selvittää uusien akuutin 
munuaisvaurion merkkiaineiden, neutrofiilien gelatinaasiin assosioituvan lipokaliinin 
(NGAL) (I) ja N-terminaalisen B-tyypin pro-natriureettisen peptidin (NT-proBNP) (II) 
osuvuutta varhaisdiagnostiikassa. Tutkimus selvitti myös vakavan palovamman 
aiheuttaman munuaisvaurion riskitekijöitä ja potilaan ennusteeseen vaikuttavia 
tekijöitä (III). Lisäksi selvitettiin keinomunuaishoidon tarvetta pitkäaikaisesti potilailla, 
jotka ovat saaneet keinomunuaishoitoa tehohoidon aikana sekä näiden potilaiden 
kuolinsyyn yhteyttä munuaisvaurioon (IV).  
 
Tutkimuksissa I ja II tutkimusaineiston muodostivat 19 prospektiivista HYKS 
Palovammakeskuksessa hoidettua tehopotilasta maaliskuun 2013 ja syyskuun 2014 
välisenä aikana. 17:llä potilaalla 19:sta plasman NGAL ylitti suositellun 
alakatkaisupisteen (>150ng/ml) ensimmäisen viikon aikana. Kahdella potilaalla 
mitattiin hyvin korkeita arvoja (>600ng/ml) ilman merkkejä akuutista 
munuaisvauriosta. NGAL sai arvon 0.62 ROC-menetelmällä määritettynä akuutin 
munuaisvaurion diagnostiikassa ensimmäisen viikon aikana, kun taas seerumin 
kreatiniini ja -kystatiini C saavuttivat huomattavasti paremman tarkkuuden. NT-
proBNP korreloi positiivisesti monimuuttujamallissa potilaiden saamaan 
kumulatiiviseen nestemäärään, korkean ikään ja negatiivisesti painoindeksiin. NT-
proBNP nousi kaikilla potilailla ensimmäisen viikon aikana.  Huomattavia yksilöllisiä 
eroja havaittiin potilailla, jotka kehittivät akuutin munuaisvaurion alkuvaiheessa ja 
heillä vaihtelu oli kaikkien suurinta. Yhteyttä akuutin munuaisvaurion ja NT-proBNP:n 
pitoisuuksien välille ei pystytty osoittamaan.   
 
Tutkimuksessa III 27.3% potilaista sai akuutin munuaisvaurion (määriteltynä 
absoluuttisesti: seerumin kreatiniini >120 μmol/l (1.4 mg/dl)). 11.2% potilaista sai 
keinomunuaishoitoa,19.8% potilaista menehtyi hoitojakson aikana. 52.9% akuutin 
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munuaisvaurion saaneista potilaista menehtyi ja vain 7.4% niistä, jotka eivät saaneet 
munuaisvauriota.  
Korkea ikä, palovamman laajuus, rabdomyolyysi ja sepsis olivat akuutin 
munuaisvaurion riskitekijöitä. Ikä, palovamman laajuus ja akuutti munuaisvaurio 
olivat kuoleman itsenäisiä riskitekijöitä, akuutti munuaisvaurio oli yksittäisenä 
tekijänä merkittävä, vetosuhteella 5.97 (95% luottamusväli: 2.2-16.2).  
Keinomunuaishoitoa saaneilla kuolleisuus ei eronnut merkitsevästi muista 
munuaisten vajaatoimintapotilaista. Akuutti munuaisvaurio nosti kuolleisuutta jopa 
pienissä palovammoissa. Toisaalta laajassakin palovammassa ennuste oli 
suhteellisen hyvä, mikäli potilaalla ei ollut munuaisvauriota. Laajoissa 
palovammoissa tosin valtaosa potilaista saa akuutin munuaisvaurion. 
 
Tutkimukseen IV kerättiin 68 potilasta, jotka ovat saaneet keinomunuaishoitoa 
marraskuun 1988 ja joulukuun 2015 välisenä aika HYKS Palovammakeskuksessa. 
52.9% potilasta menehtyi hoitojakson aikana ja seurantaan jäi 32 potilasta, jotka 
kotiutuivat palovamman hoitojaksolta. 81.3 prosentilla oma munuaistoiminta palautui 
ennen kotiutusta. 6.3% seurantaan jääneistä saivat munuaiskorvaushoitoa yli 3kk:n 
ajan.  Nämä potilaat (2kpl) saivat munuaiskorvaushoitoa jatkuvasti 10,5 ja 17kk 
ennen kuin molempien munuaistoiminta palautui. Palovamma oli kuolinsyy 35.7 
prosentilla, krooninen munuaisten vajaatoiminta 7.1 prosentilla ja 57.1 prosentilla 
kuolinsyy oli jokin muu. Yhdelle potilaalle kehittyi krooninen munuaisten 
vajaatoiminta seuranta-aikana, mikä oli myös potilaan kuolinsyy. Tutkimus ei 
havainnut, että, krooninen munuaisten vajaatoiminta olisi yleinen ilmiö vaikean 
palovamman jäljiltä, mutta sellaisen kehittyminen on mahdollista. 
  
		 12	
LIST OF ORIGINAL PUBLICATIONS 
 
This thesis is based on the following publications: 
 
I. Rakkolainen I and Vuola J. Plasma NGAL predicts early acute kidney 
injury no earlier than s-creatinine or cystatin C in severely burned 
patients.  Burns 42.2 (2016): 322-328. 
 
II. Rakkolainen I, Elmasry M, Steinvall I and Vuola J. Plasma N-terminal brain 
natriuretic peptide one week after burn injury. Journal of Burn Care & 
Research, 2018 vol. 39 (5) pp. 805-810. 
 
III. Rakkolainen I, Lindbohm JV and Vuola J. Factors associated to acute 
kidney injury in Helsinki Burn Centre in 2006-2015 Scandinavian Journal 
of Trauma, Resuscitation and Emergency Medicine (2018) 26:105. 
 
IV. Rakkolainen I, Mustonen KM and Vuola J. Long term outcome after renal 
replacement therapy in severe burns (submitted). 
 
The publications are referred to in the text by their Roman numerals. The original 
publications are reproduced with the permission of the copyright holders.
		 13	
ABBREVIATIONS 
 
ABA   American Burn Association 
ABSI   Abbreviated Burn Severity Index 
AKI   Acute kidney injury 
AKIN   Acute kidney injury network  
ANOVA  Analysis of variance 
ARDS  Acute respiratory distress syndrome 
ARF   Acute renal failure 
AUC   Area under the curve 
BE   Base excess 
BMI   Body mass index 
BNP   Brain natriuretic peptide 
BUN   Blood urea nitrogen 
CCr   Creatinine clearance rate   
CK   Creatinine kinase 
CKD   Chronic kidney disease 
COD   Cause of death 
CRP   C-reactive protein 
CRRT  Continuous renal replacement therapy 
CysC   Cystatin C 
CVVH  Continuous veno-venous hemofiltration 
ELISA  Enzyme-linked immunosorbent assay 
EMA   European Medicines Agency 
ESRD  End-stage renal disease 
FFP   Fresh frozen plasma 
FRKD  Finnish Registry for Kidney Diseases  
GFR   Glomerular filtration rate 
HES   Hydroxyethyl starch 
HF   Hemofiltration 
HD   Hemodialysis 
HDF   Hemodiafiltration 
HUH   Helsinki University Hospital 
ICD   International Classification of Diseases 
ICU   Intensive care unit 
IHD   Intermittent hemodialysis 
ITN   Ischemic tubular necrosis 
KDIGO  Kidney disease improving global outcomes 
LD50   Median lethal dose (50% likelihood of death) 
		 14	
LD100   100 percent lethal dose (100% likelihood of death) 
MB   Myoglobin 
MAP   Mean arterial pressure 
MODS  Multiple organ dysfunction score 
MOF   Multiple organ failure 
NT-proBNP N-terminal pro-brain natriuretic peptide 
NGAL  Neutrophil gelatinase-associated lipocalin 
NSAID  Nonsteroidal anti-inflammatory drug 
POC   Point-of-care 
RIFLE  Risk-injury-failure-loss-end stage renal disease  
RL   Ringer’s lactate 
ROC   Receiver operating characteristic 
RRT   Renal replacement therapy 
SCr   Serum creatinine 
SD   Standard deviation 
SLED  Sustained low-efficiency dialysis 
SOFA   Sequential organ failure assessment  
TBSA  Total body surface area 
UO   Urine output 
WHO   World Health Organization 
		 15	
1. INTRODUCTION 
 
Tens of thousands of people are 
estimated to be exposed to burns 
every year in Finland. The vast 
majority of burns heal with simple 
treatments without health care 
interventions. Around 50 people 
annually require intensive care unit 
(ICU)-level treatment for a major burn 
injury (Vaikeat palovammat 2019). 
Elderly patients and those with pre-
existing comorbidities are at greater 
risk for unfavorable outcome 
(Nitzschke et al. 2017; Pompermaier, 
Steinvall, Fredrikson, et al. 2017).  
The risk of death increases in major 
burns, especially with co-existing 
inhalation injury (Wu et al. 2016). 
Overall, major burn injuries are 
connected with remarkable mortality 
and adverse outcomes, such as acute 
kidney injury (AKI). Around 30-45 
percent of severely burned patients 
encounter AKI during their hospital 
stay. The exact proportion varies 
depending on the definition for AKI and 
on the study material.  
AKI increases significantly the 
probability of death, prolongs the ICU 
stay time and increases the economic 
burden for society. Early-onset AKI is 
encountered within days after the 
injury when caused by the lack of 
kidney perfusion due to insufficient 
circulation. Late-onset AKI is 
associated with a prolonged ICU stay, 
the administration of nephrotoxic 
antibiotics and as a part of multiple 
organ failure (MOF), which is a severe 
sequela of prolonged ICU stay (Holm 
et al. 1999).  
Fluid resuscitation is a way to 
maintain sufficient perfusion to vital 
organs at the early stage of burn 
treatment. However, administration of 
excessive amounts of fluids may lead 
to complications, such as increased 
intra-abdominal pressure, extremity 
swelling, compartment syndrome, 
pulmonary oedema and deepening of 
the burn injury (Mason et al. 2016). 
Kidneys may be protected from 
hypoperfusion by fluid resuscitation. 
Also, harmful medications can be 
discontinued, but complications can 
only be minimized in progressive AKI 
with renal replacement therapy (RRT) 
that removes excess fluid, corrects 
electrolytes imbalances and removes 
toxic metabolites.  
 
The AKI diagnosis is mainly based on 
urine output (UO) and serum creatinine 
(SCr). SCr rises in the blood after a 
decrease in the glomerular filtration 
rate (GFR); however, it poorly reflects 
the rapid alterations of GFR, although 
creatinine is a kidney-specific 
substance (Nguyen & Devarajan 
2008). Many biomarkers have been 
studied in AKI diagnostics, but most of 
them have failed to reach an 
acceptable diagnostic accuracy and 
kidney specificity to reach widespread 
use.  
The ideal biomarker for AKI 
should be cost effective, easy and fast 
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to measure, be highly accurate and 
kidney specific. Early AKI diagnostics 
would possibly help to direct 
appropriate treatment efforts to avoid 
loss of kidney function. However, it 
must be noted that no clear evidence 
exists so far that interventions (such as 
early initiation of RRT) would improve 
the outcome. 
 
Only scarce data exist about long-term 
kidney function impairment after AKI in 
severe burns. Current data from AKI 
patients hospitalized for various 
reasons suggest that the risk for 
chronic kidney disease (CKD) is 
increased even after complete 
recovery of kidney function and 
normalization of SCr (Chawla & P. L. 
Kimmel 2012; Jones et al. 2012). For 
burns, a few trials have suggested that 
burn-associated AKI increased the risk 
for future CKD development (Thalji et 
al. 2017; Helanterä et al. 2016).  
 
Many scoring metrics have been 
created to evaluate the chance of 
survival at the beginning of ICU 
treatment. Many of these, such as the 
Baux and modified Baux score, 
account for the patient's age and 
burned total body surface area 
(TBSA%) and form an estimate of the 
final outcome. The Abbreviated Burn 
Severity Index (ABSI) score accounts 
also for sex, inhalation injury and 
medical history. These formulas were 
reasonably accurate when they were 
created, but due to today’s advanced 
medical treatment and improved 
knowledge of burn care, these 
formulas tend to be too pessimistic for 
the most severely injured patients. 
These formulas still have a fair 
prognostic value; however, as long as 
we lack effective therapies for AKI, the 
prognosis for AKI patients remains 
unsatisfactory.  
 
This thesis investigated diagnostics of 
AKI, risk factors for AKI and its 
influence on prognosis in the burn 
population.  
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2. REVIEW OF 
LITERATURE 
 
2.1 Thermal injury 
 
Skin is the largest organ of the human 
body. The average surface area of an 
adult is 1.5-2 square meters. The skin 
acts as a barrier to protect the body 
from heat, cold, water loss and 
mechanical stress. The skin also acts 
as a protective barrier against 
pathogens and regulates the body’s 
temperature by isolating heat and 
removing excess heat by sweating. 
The skin plays an important sensory 
role in sensing pain, vibration and 
temperature variations.  
 
Thermal injury, such as a burn injury or 
frostbite, is tissue damage caused by 
excessive heat or cold. Burn injury is 
tissue damage caused by air, fluid, 
electrical current, radiation or a 
corrosive substance. Jackson 
presented three different areas in 1953 
that can be distinguished at the burn 
site (Jackson 1953). The zone of 
coagulation (A) is the most central part 
of the injury where all the tissue is 
irreversibly damaged. It is surrounded 
by the zone of stasis (B), where some 
tissue is still vital. The outermost part 
is called the zone of hyperaemia (C) 
  
where inflammation is present (Figure 
1). The zone of coagulation is necrotic 
and thus does not heal. The zone of 
stasis is at risk of developing necrosis 
if adequate fluid resuscitation is not 
performed to ensure sufficient 
perfusion on the site.   
Thermal injury is classified by 
the depth of the injury. The injury 
deepens within a few days of its 
occurrence and, in some cases, the 
evaluation of the final burn depth is 
postponed. A first-degree burn is 
isolated in the epidermis and heals 
conservatively without the need for 
health-care services. The most typical 
causes for a first-degree burn are sun 
burns and minor scald burns. Second-
degree burn extends to the dermis. It 
often causes swelling, pain and 
blistering and the risk of infection   
Figure 1 Jackson’s burn model   
A 
B 
      C 
		 18	
 
 
Figure 2 3rd degree contact injury from sauna stove.   
From picture archive of Helsinki Burn Centre. 
 
is increased. Superficial second-
degree burns (classified also as IIa) 
heal conservatively in two weeks. 
Deeper second-degree burns 
(classified as IIb) need a longer time to 
heal and increase the risk of excessive 
scarring and infection. Skin grafting is 
needed to reach a good functional 
result and to avoid scarring and 
infection. 
Third-degree burns (Figure 2) 
reach the subcutis and will not heal 
without surgical excision and skin 
grafting, except in very small injuries. 
Capillary reaction is absent, and the 
injury is often painless due to 
destruction of free nerve endings. The 
most extensive third-degree burns 
reach the muscle layer and even bone 
(sometimes referred as a fourth-
degree burn).   
 
2.2 Epidemiology of burn injuries  
 
Large burn injury is one of the most 
severe injuries and accounts for a 
great economic burden on society 
(Ahn & Maitz 2012). Most of the total 
costs are from the primary ICU care. 
(Latifi et al. 2017). Total costs of an 
extensive burn injury in Finland may 
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rise up to more than 500.000 EUR per 
patient (Haikonen et al. 2016).    
73% of burn injuries happen at 
home; the victim is male in 68 % of 
cases, and fire is the burn mechanism 
in 43 % of cases (American Burn 
Association 2015). At least 20,000 
people are estimated to suffer from a 
burn injury requiring medical services 
annually in Finland. However, a vast 
majority of burn injuries are minor and 
are healed conservatively with no need 
for health- care services. Fewer than 
1000 patients are hospitalized for 
burns annually in Finland, and roughly 
50-60 of them require treatment in the 
ICU (Vaikeat palovammat 2019).  
Severe burn injuries cause 
substantial changes in hemodynamics 
and tissue perfusion. Patients often 
need support in ventilation and 
circulation and also require potent pain 
management. Most of the burn injuries 
treated in the ICU are caused by flame 
in Finland. The proportion of fire-
related burn injuries among all 
hospitalized burn patients was around 
one third in 2000-2009 in Finland 
(Tanttula et al. 2018). Fire-related burn 
deaths are slightly more common in 
Finland in comparison to other western 
countries. The incidence of fire-related 
death was estimated to be 2.0 per 
100.000 inhabitants in Finland in 2009, 
whereas in New Zealand, for example, 
it was 0.8, in USA 1.0, in Sweden 1.3, 
in Denmark 1.3 and in Russia 9.8 
(World Fire Statistics Centre 2011). 
The mortality rate of burn injuries has 
been reported lower in high-income 
countries than in low-income countries 
(Smith et al. 2016). Burn injury-related 
mortality has decreased over time, 
mainly due to specialized institutions 
established only for burn treatment 
(Burn units) (Akerlund et al. 2007). The 
first burn unit was launched in 1988 in 
Helsinki and later on in 1994 in Kuopio, 
eastern Finland. Treatment of all 
severe burns in Finland was 
centralized to one national institution, 
to Helsinki Burn Centre at Jorvi 
Hospital in Espoo in the beginning of 
2016. 
 
2.3 Pathophysiology of burn injury 
 
Burn trauma increases vascular 
permeability by indirect and cytokine-
mediated pathways. This so-called 
capillary leakage causes plasma 
transfer from vessels into tissues, 
which can be seen as excessive 
swelling on the burn site. Increased 
vascular permeability allows large 
oncotic molecules to transfer from 
vessels into tissues, which decreases 
colloid osmotic pressure in vessels and 
decreases circulating blood volume. 
Circulating blood volume is even 
decreased due to excessive 
evaporation of water from burned skin. 
An animal model conducted with rats 
suggested that burn trauma decreases 
interstitial pressure in tissues; in 
addition to capillary leakage, that 
enhances the movement of fluid from 
vessels into tissues (Imbition force) 
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(Lund et al. 1988). In conclusion, these 
mechanisms decrease perfusion to 
vital organs; this lack of blood volume 
is temporarily replaced by fluid 
resuscitation. 
Burn injury not only affects 
blood vessels but also decreases 
cardiac output by systemic 
inflammation response syndrome and 
an increased number of oxygen-free 
radicals (Demling et al. 1978). 
Released catecholamines also 
increase peripheral vascular 
resistance for days after a burn injury 
(Crum et al. 1990).  
 
2.4 Fluid resuscitation in severe 
burns 
 
The Parkland formula (4ml/kg x 
TBSA%) was presented in 1968; since 
then, it has been the most used 
resuscitation formula among burn 
patients (Baxter & Shires 1968). Major 
burn injury causes fluid leakage into 
tissues by increasing vascular 
permeability. Significant amounts of 
fluids are also lost by increased 
evaporation from the burned skin 
(Friedl et al. 1989). The goal of 
successful fluid resuscitation is to 
replace this volume and secure 
sufficient perfusion to vital organs but 
not to over-resuscitate with its 
subsequent negative consequences. 
The evaluation of sufficient fluid 
resuscitation is mainly based on 
diuresis, blood pressure, tissue 
perfusion and the signs of over-
resuscitation (Holm 2000). However, 
these parameters reflect more of the 
macro-circulation and not the sufficient 
perfusion of any specific organ, such 
as the kidneys, which are vulnerable to 
inadequate perfusion (Soussi & 
Legrand 2016). The Parkland formula 
is currently widely used, though some 
updates have been announced 
(Greenhalgh 2010). The need of 
resuscitation (4ml/kg x TBSA%) 
increases relatively more in large 
burns and in paediatric patients with 
smaller body mass (Cancio et al. 
2004). A recently announced report 
observed that restrictive resuscitation 
is a risk for AKI development (Mason 
et al. 2016), but over-resuscitation may 
lead to  compartment syndrome, 
extremity swelling, wound infections, 
pulmonary oedema and even MOF 
(Saffle 2016; Mason et al. 2016). Over-
resuscitation may also deepen the 
burn wound itself.  
 
Albumin and fresh frozen plasma 
(FFP) increase intravascular oncotic 
pressure and thus help to maintain 
sufficient intravascular volume 
(Cartotto & Greenhalgh 2016). The use 
of albumin in burn resuscitation 
currently is considered probably more 
beneficial than using only Ringer´s 
Lactate (RL) (Navickis et al. 2016). A 
recent meta-analysis with 140 patients 
showed that using albumin in burn 
resuscitation provided neither an 
advantage nor disadvantage (Eljaiek et 
al. 2017). Another study of 42 burn 
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patients found that fluid resuscitation 
with albumin did not decrease multiple 
organ dysfunction score (MODS) in the 
first two weeks after arrival (Cooper et 
al. 2006). Administration of albumin to 
159 burn patients within the first 24 
hours decreased mortality and need 
for vasopressors during ICU stay (Park 
et al. 2012). Resuscitation of burn 
patients by hypertonic saline solution 
has been justified by less 
administration, therefore, potentially 
reducing the risk for volume 
complications. In a small study of 36 
severely burned patients, hypertonic 
saline groups compared with RL 
groups observed a reduced risk for 
secondary abdominal compartment 
syndrome (Oda et al. 2006). However, 
sufficient evidence to support the use 
of hypertonic saline in fluid 
resuscitation does not exist. Use of 
hypertonic saline in a wider spectrum 
has not reduced mortality in critically ill 
patients (Martin et al. 2018). 
Hydroxyethyl starch (HES) is a starch 
derivative that increases intravascular 
volume with less administration 
compared to RL. Since being 
introduced in the 1960s, it has been 
connected with increased risk of AKI 
and death in critically ill patients 
(Gattas et al. 2013). European 
Medicines Agency (EMA) discouraged 
the use of HES-infusions among the 
burn population in 2013. In general, 
these infusions should be preserved 
only to replace blood loss when other 
means are insufficient (European 
Medicines Agency 2013). These 
instructions were based on studies that 
failed to mention whether they included 
patients with severe burns (> 10-20% 
burned TBSA) (Perner et al. 2012; 
Guidet et al. 2012; Myburgh et al. 
2012; Annane et al. 2013; Brunkhorst 
et al. 2008). Earlier studies on burn 
population on pentastarch and albumin 
demonstrated a more favorable effect 
on hemodynamic parameters when 
administered 24h after injury (Waxman 
et al. 1989). Resuscitation with RL 
combined with HES in two modern 
studies including only patients with 
burned TBSA >15-20% showed that 
using HES did not increase risk of AKI 
or death, though they also did not 
support the use of HES as beneficial 
(Béchir et al. 2013; Béchir et al. 2010).  
 
2.5 Diagnosis of AKI  
 
The diagnosis of AKI has been based 
on SCr and UO for a long period of 
time. SCr is a waste product of muscle 
metabolism and is excreted from the 
circulation by the kidneys. SCr is cost 
effective (only a few EUR per 
measurement), kidney specific and 
readily available in hospitals and 
health care units. SCr's weakness is its 
inability to react in rapid changes of 
kidney function, and more than 50 
percent of kidney function must be lost 
before plasma elevation can be 
measured. The SCr baseline is 
dependent on age, sex, muscle mass 
and ethnic background, which set a 
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challenge to evaluate the GFR in 
individual patients (Nguyen & 
Devarajan 2008). Increases in SCr 
after repeated measurements are 
more informative when evaluating 
developing AKI (Lameire & Hoste 
2004). Some physiological conditions, 
such as sarcopenia, hepatic 
insufficiency, increased fluid volume 
and sepsis, decrease SCr levels, 
whereas trauma, fever and 
immobilisation increase the SCr levels 
(Clark et al. 2017). The severity of AKI 
is generally classified by Risk-Injury-
Loss-End stage renal disease (RIFLE), 
Acute Kidney Injury Network (AKIN) or 
Kidney Diseases Improving Global 
Outcomes (KDIGO) criteria (Table 1). 
All of them include SCr and UO as 
diagnostic criteria. RIFLE also includes 
decreases in GFR. Classification in 
recent papers of AKI in severe burns 
has been based mainly on either AKIN 
or RIFLE criteria (Table 1). All 
classifications have similar criteria and 
time limits for worsening of diuresis.  
However, these classifications have 
essential differences: RIFLE 
classification considers only a 
percentage-based SCr rise at the 
lowest gradings (Risk&Injury), 
whereas KDIGO and AKIN 
classifications also allow grading 
based on an absolute increase in SCr. 
Reaching a significant percentage-
based rise is more difficult in situations 
where baseline SCr is elevated 
(dehydration, CKD, rapid AKI). RIFLE 
classification sets a one-week time 
limit for deterioration, whereas AKIN 
classification limits the time period for 
only 48 hours, which rules out a slowly 
developing worsening of kidney 
function. It must be noted that even 
small increments in SCr in rapid 
sequence increase the risk of death. 
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(Gruberg et al. 2000; Lassnigg et al. 
2004; Levy et al. 2005; Praught & 
Shlipak 2005). KDIGO classification 
was created to combine the strengths 
of RIFLE and AKIN classifications. It 
allows diagnosis of mild AKI by an 
acute rise in SCr within 48h or by a 
percentage-based rise within one 
week.  
According to a systematic 
review of a heterogenous study 
population of 71000 patients, the 
RIFLE classification accurately 
predicted that mortality and the risk of 
death increased with a higher grading 
of AKI (Ricci et al. 2008). A multicenter 
study of over 16000 ICU patients 
concluded RIFLE was superior to AKIN 
classification in predicting hospital 
mortality based on kidney function 
deterioration within 48h from 
admission (Joannidis et al. 2009). 
Another study of 1973 burn patients 
demonstrated that AKIN classification 
was superior to RIFLE classification in 
predicting AKI (Chung et al. 2012). 
KDIGO-criteria are nowadays the 
golden standard in AKI definition. 
 
Several biomarkers other than SCr 
have been investigated to enhance the 
accuracy of AKI diagnostics, but many 
of them have failed to make a 
breakthrough into clinical use, mostly 
due to poor specificity to AKI and a lack 
of sufficient evidence (Zhang et al. 
Table 1 AKIN, RIFLE and KDIGO classification for AKI 
RIFLE  (Bellomo et al. 
2004)   
Risk SCr increased 1.5-2-fold from baseline OR GFR decreased > 25% < 0,5 ml/kg x h > 6h 
Injury SCr increased 2-3-fold from baseline OR GFR decreased > 50% < 0,5 ml/kg x h > 12h 
Failure SCr increased > 3-fold from baseline OR GFR decreased > 75% OR SCr > 4 mg/dL (354 μmol/L) with an acute rise 0.5 mg/dL (44 μmol/L) < 0,3 ml/kg x h > 24h OR anuria > 12h 
Loss Complete loss of kidney function > 4 weeks (Requiring RRT)  
End-stage renal disease Complete loss of kidney function > 3 months (Requiring RRT)  
AKIN (Mehta et al. 2007)   
AKIN 1 Increase in serum creatinine at least 0.3 mg/dL (26.4 μmol/L) or increase at 
least to 150-200% (1.5- to 2-fold) from baseline. 
Less than 0.5 mg/kg per hour for more than 6 
hours. 
AKIN 2 Increase in serum creatinine more than 200-300% (2- to 3-fold) from baseline. Less than 0.5 mg/kg per hour for more than 12 hours. 
AKIN 3 Increase in serum creatinine more than 300% (> 3-fold) from baseline or serum 
creatinine at least 4.0 mg/dL (354 μmol/L) with an acute increase at least 0.5 
mg/dL (44 μmol/L) or need for RRT 
Less than 0.3 mg/kg per hour for more than 24 
hours or anuria for 12 hours or need for RRT. 
      
KDIGO (Kellum et al. 
2012)   
KDIGO 1 SCr increased 1.5-1.9-fold from baseline within 7 days OR 0.3 mg/dL (26.4 μmol/L) increase in 48h < 0,5 ml/kg x h > 6h 
KDIGO 2 SCr increased 2-2.9-fold from baseline < 0,5 ml/kg x h > 12h 
KDIGO 3 SCr increased > 3-fold from baseline OR SCr > 4 mg/dL (354 μmol/L) OR need for RRT < 0,3 ml/kg x h > 24h OR anuria > 12h 
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2019). Novel biomarkers, such as 
neutrophil gelatinase-associated 
lipocalin (NGAL), N-terminal pro-brain 
natriuretic peptide (NT-proBNP) and 
cystatin C (CysC), are discussed 
further.   
 
2.6 Kidneys and aetiology of acute 
kidney injury 
 
Humans have two kidneys (Figure 3) 
that are located on both sides of the 
vertebral column at the level between 
the 12th thoracic and 3rd lumbar 
vertebrae in the retroperitoneal space 
and are surrounded by fat tissue. Each 
kidney has a blood supply via a single 
renal artery and vein, and the 
produced urine is collected by a single 
ureter leading into the bladder. 
Kidneys have an important function as 
regulators of the acid-base balance, 
extracellular fluid balance, and blood 
pressure. They remove toxic wastes 
such as urea, reabsorb minerals and 
produce erythropoietin. Kidneys 
control fluid balance by regulating the 
amount of secreted urine and its 
concentration.  
AKI (earlier referred to as acute 
renal failure (ARF)) is a loss of kidney 
function happening in a short period of 
time. At an early stage this can be 
noticed as alterations in electrolyte 
levels, mild fluid accumulation with 
peripheral oedema and a decreased 
amount of secreted urine. In severe 
AKI this is followed by increased 
concentrations of potassium and urea 
in the blood and total anuria and fluid 
accumulation into the lungs or 
peritoneal cavity. The aetiology leading 
to AKI can be distinguished as 
prerenal, renal or postrenal causes. 
Prerenal AKI is caused by insufficient 
blood and oxygen supply to the 
kidneys due to obstruction of the renal 
artery or decreased mean arterial 
pressure (MAP) and insufficient 
perfusion of the kidneys. Renal causes 
account for kidney diseases and 
destruction of nephrons. This can be 
caused by hypertension, diabetes 
mellitus, glomerulonephritis, or some 
vasculitis. Various medicines, such as 
non-steroidal anti-inflammatory drugs 
(NSAIDs), antibiotics, antihypertensive 
drugs, diuretics and imaging contrasts, 
are harmful, as is myoglobin (MB) 
released from destroyed myocytes. 
Postrenal causes include urological 
situations in which drainage of urine 
via ureters is interrupted, for example, 
by kidney stones or increased intra-
abdominal pressure or a tumor.  AKI 
develops after a severe burn injury via 
prerenal or renal causes. A postrenal 
cause is plausible due to excessive 
fluid resuscitation causing obstruction 
of ureters via increased intra-
abdominal pressure, but the burn injury 
itself is not a direct factor for postrenal 
AKI. Sometimes AKI turns into a long-
term impairment of kidneys; CKD 
means the worsening of kidney 
function for at least three months. 
ESRD means the permanent loss of 
kidney function, requiring RRT.       
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2.7 Acute kidney injury in burns 
 
AKI is a common complication after an 
extensive burn injury. The likelihood of 
AKI increases in larger burn injuries. 
Other known risk factors are high age, 
simultaneous inhalation injury, flame 
burn, the burn injury’s thickness, 
sepsis and rhabdomyolysis (Wu et al. 
2016; Stewart et al. 2013). It must be 
noted that AKI is not uncommon even 
in small burn injuries (TBSA < 20%) (L. 
A. Kimmel et al. 2018). AKI that occurs 
within five days postburn is classified 
as “early,” after which it is classified as 
“late” (Holm et al. 1999). Some studies 
however have classified AKI as  
”early,” when encountered within 14 
days postburn (Chung et al. 2009). 
Early AKI in burns is primarily caused 
by insufficient perfusion of kidneys due 
to a circulation deficit, cytokine-
mediated cardiac dysfunction, 
hypovolemia, ongoing inflammatory 
response or breakup of proteins; these 
lead to ITN (Vaidya et al. 2008; D. M. 
Davies et al. 1979; Aikawa et al. 1990; 
Mukherjee et al. 1987). Cytokines that 
are released after injury cause 
“capillary leakage,” which increases 
plasma transfer to tissues and thereby 
decreases circulating blood volume 
(Demling 2005). Early AKI is common 
especially in rhabdomyolysis and hot 
air sauna-related burn injuries when 
Figure 3 Anatomy of human kidney 
https://en.wikipedia.org/wiki/Kidney#/media/File:Blausen_0592_KidneyAnatomy_0
1.png 
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dehydration is present (Mustonen & 
Vuola 2008). Rhabdomyolysis is 
caused by damage in muscle tissue, 
which releases MB into the circulation. 
Released MB causes direct proximal 
tubule injury after several chemical 
reactions, and it may even obstruct the 
distal tubule by casts that are 
formatted (Bosch et al. 2009; Petejova 
& Martinek 2014). Rhabdomyolysis is 
diagnosed by an increase in serum 
creatinine kinase (CK), and a 
concentration of 10.000 U/l has been 
used as a cut-off value in clinical 
practice, though rhabdomyolysis has 
also been described with lower CK 
levels (de Meijer et al. 2003; Ward 
1988). Myoglobinuria often follows 
rhabdomyolysis. MB is a hemoglobin-
like protein that supplies oxygen in 
skeletal muscles, especially under 
enormous physical stress. MB is 
released from muscle cells along with 
a multiphase  cascade following this, 
causing direct proximal tubule injury 
and obstruction in distal tubules, 
causing AKI (Bosch et al. 2009). In 
rhabdomyolysis, MB usually rises 
faster than plasma CK in blood and is 
therefore preferred in diagnostics.  
 
Late AKI may follow nephrotoxic drug 
administration and is often part of MOF 
or sepsis, which are adverse outcomes 
of a prolonged ICU stay (Holm et al. 
1999). Literature shows contradictory 
results both in early and late AKI’s 
contribution to the outcome (Witkowski 
et al. 2016; Schneider et al. 2012). The 
differences in outcomes are likely 
explained by differences in the study 
populations and the definition of AKI 
that is used. Based on the aetiology of 
AKI, early AKI can be treated with 
circulation supportive methods, like 
fluid resuscitation and vasoactive 
drugs. RRT may be initiated in severe 
AKI to remove harmful substances like 
ammonium and urea from the blood. 
Whereas developing early AKI may 
subside rapidly with fluid resuscitation, 
late AKI is often associated with sepsis 
and as a part of MOF, a poorly 
manageable state (Steinvall et al. 
2008). Early studies in the 1990s 
concluded that early AKI is associated 
with better outcomes compared to late 
AKI (Davies:1994ut; Aikawa et al. 
1990). Since then, several studies 
have contradicted these observations 
(Witkowski et al. 2016; Holm et al. 
1999; Mustonen & Vuola 2008). It must 
be emphasized that all these studies 
use different definitions for AKI, for 
early and late onset AKI, as well as 
using heterogenous patient selection 
and exclusion criteria, which makes 
the comparison of these studies 
impossible.  
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Table 2 Incidence and mortality of AKI in burned patients on previous studies 1) Year(s) when data collected or published (pub.) 
 
        
Authors Years1 Number of 
patients 
Incidence of 
AKI (%) 
Incidence of 
RRT (%) 
AKI Mortality 
(%) 
Inclusion criteria Criteria for AKI 
Cason JS  
 
1953-1956  3690 1.3  100   
Evans AJ  1953-1966 602 0  0 Pediatric burn patients  
Cameron and Miller-
Jones  
1953-1966 720 3.1  95.5 Pediatric burn patients Blood urea > 1mg/ml 
Vertel and Knochel  1960-1966 1050 2.3  87.5 All patients admitted BUN > 40mg/dl or 
nonprotein nitrogen 
> 50 mg/dl 
Cameron  1967 110 20  95.5 Children, > 15% burned 
TBSA 
Blood urea > 1 
mg/ml 
Davies et al  1958-1979 1064 2.6 2.4 85.7/88 All patients admitted Need for RRT 
Tweddell et al  1964-1983 91 4.4  100 Pediatric burn patients with 
hematuria 
 
Hubsher et al  1984-1985 5  100 80 Burn patients, need for RRT  
Planas et al  1982 (pub.) 29 38   2-3 dg. burn, >30% TBSA  
Schiavon et al  1988 (pub.) 20 20  100  SCr > 133 μmol/l  
Aikawa et al  
 
1990 (pub.) 158 10.8  88.2  Clearance < 
50ml/min or BUN > 
50mg/dl or SCr > 
175μmol/L 
Saffle et al  1987-1990 529 9.5  46 All patients, length of stay > 
72h in ICU 
Thermal Injury 
Organ Failure Score 
(moderate: SCr > 
221 μmol/L) 
Davies et al  1994 (pub.) 18 burn units < 1%  80 A questionnaire study Need for RRT 
Schreidan et al  1989-1994 56 68 21 100 Succumbed patients Serum BUN > 100 
or SCr > 3.5 or UO < 
500ml/24h 
Leblanc et al  1987-1994 970  1.6 81.3 All patients admitted Fluid retention or 
pulmonary oedema, 
or S-Urea > 35 
μmol/L 
Jeschke et al  1966-1997 5000 1.2 0.7 73 Children, all patients 
admitted 
UO < 0,5ml/kg x h 
>36h or Serum urea 
nitrogen/creatinine 
ratio < 20 or SCr > 
177μmol/L or need 
for RRT 
O’Keefe et al  1989-1998 4927 1.9   All patients admitted  
Holm et al  1994-1998 328 14.6 14.6 85.4 Patients with deep burn, 
TBSA > 10% 
Need for RRT 
Tremblay et al  
 
1995-1998 353 3.4 3.4 50 All patients admitted Need for RRT 
Chrysopoulo et al  1981-1998 1404 5.4 4.8 88.2 Patients with TBSA burned 
> 30%, >10% 3 dg. burn 
3 of these: UO < 
350ml/36h, BUN/Cr 
< 20, SCr > 
177μmol, need for 
RRT 
Barrow et al  1982-1999 133 30.1   Children, >50% TBSA 2 of these: UO< 
0.4ml/kg x h >36h, 
BUN >50 mg/dl, U-
Cr/S-Cr >20, SCr > 
2mg/dL 
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Table 2 continues 
Cumming et al  
 
 
1998-1999 85 3.5   Patients with > 20% TBSA MODS (3-4, SCr > 
350 μmol) 
Spies et al  1996-2000 33 15.2  80 Children, TBSA >80% or 
>70% full-thickness 
SCr > 20mg/L 
Kim et al  2000 147 19 2 100 Patients with > 30% TBSA 
2-3 dg. 
SCr > 177 μmol/L 
Cooper et al  
 
 
1999-2001 42 14.3   Patients with > 20% TBSA MODS (3-4, SCr > 
350 μmol/L) 
Mustonen and Vuola  
 
 
1988-2001 238 39.1 13.4 44.1 All patients admitted ICU SCr ≥ 120 μmol/L 
Sun et al  1997-2003 6  100 83.3 Burn patients >30% TBSA, 
requiring RRT 
 
Coca et al  1998-2003 304 27 3.6 28 Patients with > 10% TBSA RIFLE  
Gudaviciene et al  2000-2003 138 10.1  85.7 Patients aged 16-80 with 
10-80% burned TBSA% 
 
Garner et al  1994-2004 3118  1.4 66 All patients admitted  
Steinvall et al  
 
 
1997-2005 127 24 3.1 35.5 Patients with > 20% TBSA RIFLE 
Mariano et al  
 
2003-2005 29 65.5 51.7 52.6 Burn patients with septic 
shock 
RIFLE 
Lopes et al  2004-2005 126 36  47 All patients admitted RIFLE 
Kuo et al  2004-2006  145 35.9  50.9 Patients aged >18 years KDIGO  
Mosier et al  
 
2008 (pub.) 221 28.1 11.3 35.5 Patients with > 20% TBSA, 
aged >18 years 
RIFLE 
Chung et al  2003-2008 1973 33.2 4.1 21 Patients with age >18 years AKIN 
Stewart et al  
 
 
2003-2008 692 23.8 5.9 24.2 Burned military casualties RIFLE 
Schneider et al  
 
 
 
2006-2008 221 47.1 11.3 35.6 Patients aged >18, >20% 
TBSA 
RIFLE 
Palmieri et al  
 
 
2006-2008 123 45.5  8.9 Children with > 10% TBSA RIFLE 
Sabry et al  2009 (pub.) 40 22.5 10 22.2 Patients with 20-70% TBSA SCr >2mg/dL or 
BUN >25mg/dL 
Hu et al  2006-2010 396 38.1 4 28.5 Patients with > 30% TBSA, 
Age 18-75 
RIFLE 
Palmieri et al  2010 (pub.) 60 53.3  34.4 Patients with > 20% TBSA  RIFLE 
Damkat-Thomas et al  2011 (pub.) 41 41 12.2 35 All patients admitted RIFLE 
Clemens et al  2003-2011 830 48.2  43 All patients admitted ICU, 
mechanical ventilation 
KDIGO  
Sánchez- Sánchez et 
al  
 
2008-2011 165 19.4 9.1 50 TBSA 15-85%, Age 16-80 RIFLE 
Noshad  2008-2011 100 76  38.2 All patients admitted RIFLE 
Yavuz et al  2009-2011 22 27.3  
 
 
 Paediatric burn patients, 
>10% TBSA 
RIFLE 
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Table 2 continues  
Estrada et al  2002-2012 146 4.8  87.5 TBSA >25%, (>20% in >40-
yr, >10% 3rd burns, aged 
>14 yr.) 
 
Queiroz et al  2010-2012 293 26.3 17.7  Patients aged >18 KDIGO 
Hong et al  2011-2012 45 24.4 11.1 72.2 Patients aged >18, >20% 
TBSA 
RIFLE 
Yang et al  2011-2012 90 61.1 24.4 69.1 Patients aged >18, >20% 
TBSA 
RIFLE 
Ren et al  2013 95 11.2 5.3 36.4 Patients aged 15-65 KDIGO  
Thalji et al  2009-2013 1476, register 
study 
20.7  62.4 Patients with >20% TBSA ICD-9 coding 
Yim et al  2012-2013 97 41.2 23.5 52.5 Patients aged >18 AKIN 
Witkowski et al  2012-2013 225 40 4 88 Patients with >30% TBSA GFR < 60ml/min at 
admission or GFR 
decrease >75% from 
admission or UO 
<500ml/24h 
Kym et al  2012-2013 85 56.5 25.9 64.6 Patients aged >18, >20% 
TBSA 
RIFLE 
Lavrentieva et al  2006-2014 64 57.8 28.1 62.2 Patients with septic shock, 
aged >18, >10% TBSA 
KDIGO  
Liang et al  2009-2014 59 39   Patients, TBSA >40% 2-3 
dg 
RIFLE 
Kimmel et al  2010-2014 267 22.5  8.3 Patients, TBSA >10% RIFLE 
Howell et al  2015 (pub.) 15 46.7   Patients aged >18, >20% 
TBSA 
RIFLE 
Sen et al  2015 (pub.) 30 46.7 10  Patients aged >18, >20% 
TBSA, 2-3 dg. 
RIFLE 
Clark et al  2008-2015 1040 57.8 5.6 20.3 Burn > 18yrs patients 
admitted to ICU 
AKIN, without 
diuresis criterion 
Dépret et al 2012-2015 87 44.8 24.1 82 Patients aged >18, >20% 
TBSA 
KDIGO 
Chun et al   2014-2015 76 42.1 26.3 68.8 Patients aged >18, >20% 
TBSA 
AKIN 
Koniman et al 2008-2016 201 65.6 21.9 34.1 All patients admitted SCr rise more than 
26.5 μmol/L 
Kim et al 
 
2015-2016 84 41.7 21.4 82.9 Patients aged >18, >20% 
TBSA 
AKIN 
Chung et al 
 
2018 (pub.) 170 94.1 100 50 RRT patients, >18 years AKIN 
Pooled studies        
        
Bruesselaers et al  1960-2009 34771, 57 
studies 
14.5 (median)  55.2  23 different 
definitions 
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Table 2 continues 
Wu et al  2007-2016 3941, 18 
studies 
39.6  30.6  RIFLE 
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The first survivors from AKI caused by 
burn injury were reported in the early 
1960s. Over time the prognosis has 
improved notably, though AKI still 
increases the risk of death. 
(Brusselaers et al. 2010). Table 2 
shows studies conducted on burn 
patients, the incidence of AKI/RRT and 
the mortality of AKI patients. The 
variety of study populations and over 
20 different definitions for AKI make it 
impossible to compare the studies with 
each other. Even more definitions for 
AKI have been presented during past 
decades (Brusselaers et al. 2010). In 
conclusion, even in the 21st century, 
AKI is a common complication after 
severe burn injury. Mortality has 
decreased over time but still remains at 
a level of tens of percents.  
 
2.8 Treatment of AKI 
 
No specific curative treatment exists 
for AKI. The goal of interventions is to 
secure a sufficient perfusion of the 
kidneys by fluid resuscitation and, if 
necessary, by administration of 
vasopressors, which increase MAP 
and/or cardiac output. Treating AKI by 
urine alkalinization with sodium 
bicarbonate or by administration of 
mannitol has been proposed, but 
studies have not supported this as 
beneficial (B. Yang et al. 2014; Brown 
et al. 2004). A low-dose dopamine 
infusion increased the creatinine 
clearance rate (CCr) in eight ICU 
patients, but the effect was lost within 
48 hours, likely due to upregulation of 
dopamine receptors in kidney arteries 
(Ichai et al. 2000). Administration of a 
dopamine receptor agonist, 
fenoldopam, reduced the risk of RRT 
and mortality according to a meta-
analysis consisting of 1290 
heterogenous, critically ill ICU patients 
from 16 studies (Landoni et al. 2007). 
In a randomized multicenter study of 
667 cardiac surgery patients, 
fenoldopam did not reduce mortality or 
need for RRT in the 30-day follow-up 
but caused more hypotension (Bove et 
al. 2014). In a retrospective study of 
severely burned patients, 
administration of fenoldopam 
increased UO, but the study did not 
provide evidence for reduced mortality 
or a decreased need for RRT 
(Simmons et al. 2010). Many trials are 
ongoing in which novel 
pharmacological agents are being 
investigated to learn if they could be 
helpful in preventing AKI (Benoit & 
Devarajan 2018). 
 
RRT may be considered in the most 
severe AKI cases to manage life-
threatening situations such as 
hyperkalemia or severe fluid 
accumulation. The modern RRT 
techniques were launched in the early 
1960s (Scribner et al. 1960; Pendras et 
al. 1961). Table 2 shows that the need 
for RRT after AKI is notably rare when 
considering the incidence of AKI during 
the past decades. Techniques to 
perform RRT include hemodialysis 
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(HD), hemofiltration (HF) and 
hemodiafiltration (HDF) as intermittent 
or continuous. Sustained low-
efficiency dialysis (SLED) is a modified 
dialysis technique in which the dialysis 
duration is extended up to 12 hours to 
improve hemodynamic tolerability.  
No consensus exists about 
whether early initiation of RRT reduces 
mortality or if some RRT techniques 
are superior to others. Continuous 
renal replacement therapy (CRRT) is 
usually better tolerated in patients with 
labile hemodynamics. A retrospective 
cohort of 232 ICU patients compared 
SLED vs. CRRT in critically ill patients. 
It observed no significant difference in 
30-day mortality (Kitchlu et al. 2015).  
In general ICU patients in a 
randomized prospective multi-center 
study on 1124 critically ill patients 
showed no reduced 90-day mortality 
when intensive dialysis therapy was 
compared to less-intensive therapy 
(RENAL Replacement Therapy Study 
Investigators et al. 2009). A recent 
single-center randomized study of 231 
critically ill patients showed 
significantly reduced 90-day mortality 
in patients with early RRT initiation vs. 
delayed RRT initiation (Zarbock et al. 
2016). Another multi-center 
randomized trial showed no difference 
in 60-day survival when accelerated 
RRT initiation was compared to a 
delayed strategy (Gaudry et al. 2016). 
Another study showed no difference in 
in-hospital mortality nor in 90-day 
mortality between accelerated vs. 
standard RRT initiation in 100 critically 
ill patients (Wald et al. 2015).  
 
Protective evidence of RRT to reduce 
mortality among burn patients is minor.  
A small retrospective cohort of 28 burn 
patients who received continuous 
veno-venous hemofiltration (CVVH) 
showed a reduced risk of mortality 
compared to matched controls (Chung 
et al. 2009), as well as a retrospective 
study of 18 military casualties who 
underwent CRRT compared to 
matched controls (Chung et al. 2008). 
A randomized clinical trial investigated 
whether early RRT initiation improves 
the prognosis compared to standard 
care in burn patients suffering septic 
shock (ClinicalTrials.gov ID: 
NCT01213914). The study was 
terminated ahead of time due to slow 
enrollment. It concluded early RRT 
initiation to improve organ dysfunction; 
however, no difference in survival was 
noted (Chung et al. 2017). 
 
2.9 Long term outcomes after AKI in 
severe burns 
 
A systematic review comprising 13 
studies showed that AKI increased the 
risk for CKD and end-stage renal 
disease (ESRD) after discharge in 
general hospitalized patients (Coca et 
al. 2012). However, evidence suggests 
that hospitalized patients with mild AKI 
whose kidney function recovers 
generally do not have an increased risk 
for ESRD (Choi et al. 2010), though 
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conflicting evidence has been 
proposed based on a Canadian study 
of 41327 patients with AKI (Wald et al. 
2012). 
 There is only moderate 
evidence of long-term renal outcomes 
in severe burns after RRT. A few 
studies have reported that kidney 
function in most patients recovers 
before discharge (Soltani et al. 2009). 
An American multicenter study 
reported 21% of patients as being 
dependent on dialysis at the moment 
of discharge and 9% six months after 
discharge (Chung et al. 2018). The risk 
of ESRD after burn injury is rare, 
according to a Finnish register study. 
Around 0.1% of all burn patients 
treated as in- or outpatients between 
1998-2012 in Finland suffered from 
ESRD after burn injury (43 patients). 
88.4% of patients (38 patients) had 
diagnosed kidney disease before their 
burn injury. Researchers concluded 
that the burn injury might have been a 
plausible cause for ESRD in five out of 
41179 patients but, unfortunately, 
further explanations were not given 
(Helanterä et al. 2016). Another 
American register study concluded that 
AKI was a risk factor for CKD and 
chronic RRT by multivariable 
regression analysis, adjusted with co-
morbidities one year after injury (Thalji 
et al. 2017). However, recent evidence 
suggests that pre-existing chronic 
impaired kidney function before a burn 
injury is an individual risk factor for in-
hospital mortality at 30 and 60-days 
since injury (Knowlin et al. 2018).  
 
2.10 Novel biomarkers in AKI 
diagnostics 
 
2.10.1 Cystatin C (CysC)  
 
CysC was discovered in 1961 
(Clausen 1961). It is a 13.4 kD-sized 
proteinase inhibitor found in every 
nucleated cell in the human body. 
CysC is normally filtered through 
glomeruli and reabsorbed in the 
proximal tubule. Decreases in GFR 
increase CysC concentrations in 
plasma, which can be measured. CysC 
concentrations are independent of 
age, sex, body and muscle mass, 
making it a more ideal biomarker for 
AKI due to less confounding factors 
affecting the values (Herget-Rosenthal 
et al. 2004). Plasma CysC has been 
evaluated as a fair biomarker for 
detecting AKI in general ICU patients 
(Ahlström et al. 2004; Herget-
Rosenthal et al. 2004), after liver 
transplantation (Hei et al. 2008) in 
emergency department setting (Soto et 
al. 2010) and after cardiac surgery in 
adults (Haase-Fielitz et al. 2009; 
Haase, Bellomo, Devarajan, Ma, et al. 
2009; Ristikankare et al. 2010) and 
children (Krawczeski et al. 2010; 
Zappitelli et al. 2011) 
Controversial and limited 
evidence exists when using CysC for 
detecting AKI among burn population. 
Serum CysC has been evaluated in 
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two papers as superior to SCr with 
adult burn patients (Yim et al. 2015; X. 
Cai et al. 2012); however, recent 
studies have not been able to confirm 
it as superior to SCr (Kym et al. 2015; 
H. T. Yang et al. 2014) 
 
2.10.2 Neutrophil gelatinase-
associated lipocalin (NGAL) 
 
NGAL is a 25kD-sized molecule of the 
lipocalin family, that was discovered in 
human neutrophils in 1994 (Xu et al. 
1994). NGAL was discovered 
thereafter in the epithelia of colon, 
trachea, kidney, stomach and lungs, 
where it is expressed in very low 
concentrations under normal 
conditions (Xu & Venge 2000). NGAL 
is found in three different isoforms: a 
25kD monomer, a 45kD dimeric and a 
135kD heterodimeric form. (Kjeldsen 
et al. 1993). Kidney tubule cells 
express the monomeric and dimeric 
form, whereas neutrophils only 
express the dimeric form (L. Cai et al. 
2010). Elevated concentrations of 
NGAL have been discovered in 
patients with severe peritonitis 
(Axelsson et al. 1995), cystic fibrosis 
(Eichler et al. 1999), chronic 
obstructive pulmonary disease 
(Ekberg-Jansson et al. 2001), 
rheumatoid arthritis (Bläser et al. 1995) 
and also in professional swimmers 
constantly exposed to chlorinated 
water (Helenius et al. 1998). The 
diagnostic value of NGAL for kidney 
tubular injury was discovered in 2003 
in mice (Mishra et al. 2003), and the 
first human study was conducted in 
2005 (Mishra et al. 2005). The 
concentrations of NGAL rise rapidly in 
blood and urine  in damaged kidney 
epithelium after ITN (Vaidya et al. 
2008). 
 
NGAL has been widely studied in AKI 
diagnostics in various study 
populations and settings. Plasma and 
urine NGAL were evaluated as good 
biomarkers in predicting contrast-
induced AKI (K. Wang et al. 2016), AKI 
after cardiopulmonary bypass in adults 
and children (Moriyama et al. 2016; 
Parikh, Coca, et al. 2011; Parikh, 
Devarajan, et al. 2011) in an 
emergency department setting 
(Nickolas et al. 2008; Shapiro et al. 
2010) and in the general ICU setting 
(Makris et al. 2009; Constantin et al. 
2010). Urine NGAL has been 
evaluated as slightly more accurate 
than plasma NGAL in AKI diagnostics 
in various patient settings by a meta-
analysis (Haase, Bellomo, Devarajan, 
Schlattmann, et al. 2009). A Finnish 
study, however, noticed urine NGAL to 
be a poor predictor of AKI or death in 
critically ill patients (Nisula et al. 2014).  
 
Very limited evidence exists for using 
NGAL among the burn population, only 
six studies with a total of 343 adults 
(Howell et al. 2015; Hong et al. 2013; 
Sen et al 2015; Chun et al. 2017; Yang 
2014; Depret et al. 2018) and one 
study with 22 children (Yavuz et al. 
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2014) have been published since 
09/2019. Many of them concluded that 
plasma or urine NGAL are superior to 
SCr in AKI diagnostics in the early 
phase after burn injury. A study of 90 
adults showed plasma and urine NGAL 
to be superior to SCr in predicting early 
AKI, but they failed to predict late-
onset AKI (H. T. Yang et al. 2014). A 
recent study of 76 adults concluded 
that serum NGAL was significantly 
elevated in AKI patients at days 7, 14, 
21 and 28 after burn injury. NGAL 
levels were affected by operations, 
septic shock and AKI. Serum NGAL 
was not independently associated with 
mortality. The study concluded that 
NGAL is affected not only by AKI, 
which must be accounted as a 
limitation (Chun et al. 2017). A recent 
study of 84 adults concluded that SCr 
was more accurate than NGAL in 
predicting AKI development in the first 
week after burn injury. The accuracy of 
SCr slightly weakened in weeks two to 
five, whereas the diagnostic 
performance of serum NGAL remained 
poor during the whole study period 
(AUC: 0.51-0.67) (Y. Kim et al. 2018). 
A study of 87 severely burned patients 
showed that elevated plasma NGAL on 
admission increased risk for death, 
dialysis or unrecovered kidney function 
for at least 90 days (Dépret et al. 
2018). 
 
NGAL was thought to be the “troponin 
of the kidneys” (Devarajan 2010). 
However, this insight has faced 
criticism due to incomprehensive 
knowledge of the NGAL as a 
biomolecule. Current laboratory 
equipment is claimed to be incapable 
of distinguishing the three different 
isoforms of NGAL, which makes it 
impossible to distinguish NGAL 
originating from the kidneys (Legrand 
et al. 2013, Glassford et al. 2013). 
Many other factors, such as systemic 
inflammation and potentially circulating 
extra-renal NGAL, may confound 
measurements, and they create a 
major problem when making clinical 
judgements (Mårtensson & Bellomo 
2014). 
 
2.10.3 Brain natriuretic peptide 
(BNP) 
 
BNP was discovered in 1988. It is 
related to the natriuretic peptide family, 
which has an essential role regulating 
extracellular fluid volume. It is a 
neuroendocrine ligand secreted from 
cardiac myocytes after ventricular 
stretching (Ruskoaho 1992). BNP and 
NT-proBNP are both formed from 
proBNP, which is enzymatically 
dissociated during its secretion 
process. BNP has a 20 min. half-life vs. 
NT-proBNP’s 120 min. The clearance 
of NT-proBNP is processed via 
kidneys, and decreased GFR tends to 
raise NT-proBNP levels in plasma 
(Martinez-Rumayor et al. 2008; H.-N. 
Kim & Januzzi 2011; Tagore et al. 
2008). NT-proBNP levels increase with 
age; this effect is accounted for in the 
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reference values (Maisel et al. 2008). 
A lower BNP was observed to be 
associated with a higher body mass 
index in noncardiac patients (BMI) (T. 
J. Wang et al. 2004). NT-proBNP has 
a validated diagnostic value in 
congestive heart failure, a condition 
that causes fluid accumulation and 
stretching of the cardiac muscle 
(Maisel et al. 2002; McCullough et al. 
2002). Elevated NT-proBNP levels 
have also been measured as an effect 
of right ventricular stretch in acute 
pulmonary embolism (Coutance et al. 
2008) and in acute respiratory distress 
syndrome (ARDS) (Maeder et al. 2003; 
Yap et al. 2004). NT-proBNP and BNP 
have also been investigated in several 
noncardiac clinical settings: In general 
ICU patients, BNP was elevated in 
those who showed worsening of 
kidney function at the early phase of 
the ICU stay (de Cal et al. 2011). Two 
studies showed opposite results when 
evaluating NT-proBNP as a marker for 
worsening kidney function in patients 
who were admitted to hospital due to 
acute decompensated heart failure 
(Legrand et al. 2014; Yamashita et al. 
2010). A multicenter study showed that 
elevated NT-proBNP levels predicted 
mortality during hospitalization in 
general ICU patients suffering from 
sepsis or severe shock (Varpula et al. 
2007). Two minor studies on general 
ICU patients have shown an 
association between NT-proBNP and 
the Sequential Organ Failure 
Assessment (SOFA) score (Guaricci et 
al. 2015; Piechota et al. 2006). The 
SOFA score reflects the severity of 
organ dysfunction during an ICU stay 
(Vincent et al. 1996).   
 
Minor evidence of BNP or NT-proBNP 
exists among the burn population: NT-
proBNP was elevated not only in those 
burn patients who developed 
abdominal compartment syndrome or 
pulmonary oedema as a sign of 
excessive fluid  resuscitation (Howell 
et al. 2015; Friese et al. 2007) but also 
in patients who developed sepsis after 
burn injury (Paratz et al. 2014). High 
BNP at day three after burn injury was 
associated with successful fluid 
resuscitation and improved outcome 
(de Leeuw et al. 2011). A Swedish 
study concluded that NT-proBNP 
correlates with the SOFA score and 
the size of the burn injury (Lindahl et al. 
2013).  
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2.11 Prediction of prognosis in burn 
patients 
 
Many scoring formulas (Table 3) have 
been invented to judge the severity of 
burn patients’ situations and 
additionally to evaluate their prognosis 
after trauma (Hussain et al. 2013). The 
Baux score  was the first scoring 
system to predict the change of 
survival after injury (S. Baux). It takes 
into account the patient’s age and 
burned TBSA%. When published in 
1961, a score over 100 was 
considered to be a predictor of certain 
death and LD50 yield around 75. The 
treatment of burn patients has 
experienced major improvements 
since then, and the predictive value of 
the Baux score is doubted now. Osler 
et al. presented a modified Baux-score 
in 2010. They showed a 0.956 AUC for 
the modified Baux score in predicting 
death during a hospital stay with 39888 
patients treated from 2000-2007 (Osler 
et al. 2010). Several studies of burn 
patients treated between 1987 and 
2013 showed the modified Baux score 
to have 0.84-0.96 AUC in predicting 
death during a hospital stay (Table 4). 
Modern studies of LD50 for Baux score 
have set it at around 100 and LD100 at 
around 130 for patients treated in 
1977-1996 (Bang & Ghoneim 1996; 
Wibbenmeyer et al. 2001). The latest 
studies performed from 2000-2008 
showed improvements in survival: 
LD50 reached 110 and LD100 160 with 
5280 burn patients (Roberts et al. 
 
Table 3 ABSI, Baux and modified Baux 
score 
 
The Abbreviated Burn Severity Index (ABSI) 
(Tobiasen et al. 1982) 
 
Parameter Finding Points 
Sex Female 
Male 
1 
0 
Age (years) 0-20 
21-40 
41-60 
61-80 
81-100 
1 
2 
3 
4 
5 
Inhalation 
injury 
Yes 
No 
1 
0 
Full-thickness 
burn 
Yes 
No 
1 
0 
Burned 
TBSA% 
1-10 
11-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
91-100 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
   
ABSI score and prediction 
ABSI Threat to life Probability of 
survival 
2-3 
4-5 
6-7 
 
8-9 
9-11 
≥ 12 
Very low 
Moderate 
Moderately 
severe 
Serious 
Severe 
Maximum 
≥ 99 
98 
80-90 
 
50-70 
20-40 
≤ 10 
   
Baux score (S. Baux) 
 
Baux score = Patient’s age + TBSA% 
The modified Baux score (Osler et al. 2010) 
 
The modified Baux score = Patient’s age + 
TBSA% + 17* (*When inhalation injury 
exists) 
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2012). The AUC for the Baux score in 
predicting death was evaluated to be 
0.90-0.93 in burn patients treated in 
1977-1996 and 2003-2009 (Table 4). A 
recent Swedish study resulted in an 
AUC as high as 0.97 for the Baux score 
in predicting death in the Swedish 
population between 1993 and 2012 
(Steinvall et al. 2016) (Table 4). The 
Baux score has been notably higher in 
nonsurvivors (Rao et al. 2006), which  
correlates with hospital stays after 
injury (Gravante et al. 2007).  
The ABSI score was published 
in 1982 based on a study population of 
590 patients from two burn centers 
(Tobiasen et al. 1982). It includes age, 
sex, TBSA%, presence of co-
morbidities, inhalation injury and full-
thickness burn as criteria (Table 3). 
Several studies have shown that an 
elevated ABSI score increases the risk 
of death in burn patients (Büttemeyer 
et al. 2004; Rao et al. 2006; Germann 
et al. 1997; Forster et al. 2011; 
Lumenta et al. 2008; Lionelli et al. 
2005; Wibbenmeyer et al. 2001) and 
ABSI-score correlates with the length 
of   a hospital stay (Gravante et al. 
2007). A retrospective analysis of 2813 
patients treated between 1968 and 
2008 confirmed ABSI to be a fair 
predictor of outcome among the burn 
population (Forster et al. 2011). The 
AUC of ABSI in predicting death during 
a hospital stay has varied between 
0.82 and 0.91 in patients treated 
between 1977 and 2015 (Table 4). 
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Table 4 ABSI, Baux and modified Baux score in predicting death after burn injury 
         
 Years Number of 
patients 
AUC-
ABSI 
AUC-Baux AUC-
Mod. 
Baux 
Inclusion 
criteria 
Average or 
median (m) 
TBSA% 
Average or 
median (m) 
age 
Wibbenbeyer et al. 2001 1977-1996 308 0.82 0.93  Age > 60 
years 
13 (m) 71.5 
Osler et al. 2010 2000-2007 39888   0.96 Register 
study 
9.7 30.6 
Tahir et al. 2009 2007-2008 80 0.97   TBSA > 20% 42 31 
Dokter et al. 2014  1987-2009 4389   0.96 All patients 
admitted 
6 (m) 27 (m) 
Tsurumi et al. 2015  2003-2009 333 0.86 0.90 0.91 Age > 16, 
TBSA > 20% 
  
Tsurumi et al. 2015 2003-2009 189 0.83 0.81 0.85 Age < 16, 
TBSA > 20% 
  
Hussain et al. 2013 2006-2010 927 0.97 0.89  Register 
study 
  
Yoon et al. 2017 2007-2010 84 0.76   RRT patients, 
TBSA > 20 % 
59.5 52 
Brusselaers et al. 2013 2009-2011 261 0.84-
0.86 
 0.84 All patients 
admitted 
25.8 16.6 
Steinvall et al. 2016 1993-2012 1613 0.96 0.97 0.98 All patients 
admitted 
12.4 33.7 
Queiroz et al. 2016  2010-2012 293 0.89   Age > 18  22 (m) 38 (m) 
Pantet et al. 2016 1996-2013 492 0.91  0.92 All patients 
admitted 
20 (m) 42 (m) 
Heng et al. 2015  2004-2013    0.92 Age > 18, 
TBSA > 15% 
36.5 (m) 45.7 (m) 
Smith et al. 2016  2013-2015 748 0.90  0.89 All patients 
admitted 
9.7 17.1 
Salehi et al. 2017 2015-2016 238 0.86  0.84 Age > 18 
years 
58.3 38.3 
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3. AIMS OF THIS STUDY 
 
This study’s purpose was to investigate the usefulness of novel biomarkers in AKI 
diagnostics and their behaviour during fluid resuscitation after severe burn injury. An 
additional goal was to investigate factors associated with the prognosis and 
development of AKI and which factors predict death, AKI and long-term 
complications after receiving RRT for a severe burn. We also wanted to establish if 
a linkage exists between severe AKI and CKD and if they associate on the patients’ 
long-term mortality.  
 
The specific aims of this thesis were to investigate: 
 
1. If plasma NGAL is a more rapid and accurate biomarker in AKI diagnostics 
than SCr or CysC during the first week after a severe burn injury (I) 
2. If plasma NT-proBNP is useful in AKI diagnostics within the first week after a 
burn injury and does it reflect the amount of fluids given in resuscitation after 
injury (II) 
3. What are the risk factors for AKI and death after a severe burn injury (III) 
4. If Baux, modified Baux or ABSI score are accurate in predicting death after 
severe burn injury (III) 
5. If the prognosis of early AKI differs from that of the late AKI (III) 
6. If burn patients stay dialysis dependent after severe AKI (IV) 
7. If CKD is a common sequela after severe AKI and has it enhanced long-term 
effect on mortality (IV) 
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4. MATERIALS AND 
METHODS 
 
This thesis consists of four human 
studies. Studies I-II are prospective 
cohort studies, and studies III-IV are 
retrospective cohort studies.  
 
4.1 NGAL (I) and NT-proBNP study 
(II)  
 
The prospective studies were carried 
out between March 2013 and 
September 2014 in the Helsinki Burn 
Centre. The inclusion criteria were 
TBSA% above 20 or above 15 for 
patients aged over 60 years. All 
enrolled patients gave their informed 
consent for participation in these 
studies. When the patient was unable 
to give consent, it was obtained from 
the relatives. The following parameters 
were collected from all patients: Age, 
sex, BMI, TBSA%, burn mechanism, 
need for intubation or ventilation, 
escharotomies, ABSI (Tobiasen et al. 
1982) and SOFA scores (Vincent et al. 
1996), co-morbidities, need for RRT, 
duration of ICU stay and outcome. 
Table 5 shows the laboratory 
parameters measured.  
  
All laboratory parameters were 
analysed via Helsinki University 
Central Hospital (HUCH) laboratory 
services (HUSLAB) except plasma 
NGAL (I) and NT-proBNP (II), which 
were analysed by Triage®, a point-of-
care device (POC) (Alere Inc., 
Waltham, MA, USA) that determines 
the levels of both biomarkers from the 
same test kit (Alere Triage® 
CardioRenal Panel) by an enzyme- 
linked immunosorbent  assay (ELISA). 
It detects NGAL in the range of 15 to 
1300 ng/ml and NT-proBNP in the 
range of 5 to 5000 pg/ml. Quality 
control procedures were performed 
according to the guidance of the 
manufacturer.  
 
4.2 AKI study (III) 
 
All ICU patients treated in Helsinki 
Burn Centre between January 2006 
and December 2015 were collected. 
Excluded patients had TBSA% less 
Table 5 Laboratory measurements 
of studies I and II 
  
NGAL 
study (I) 
 
  
Plasma NGAL, SCr and CysC 
§ Arrival, 12, 24,36,48h. Thereafter 
daily until day 7.  
  
NT-proBNP study (II) 
  
Plasma NT-proBNP 
§ Arrival, 12, 24,36,48h. Thereafter 
daily until day 7. 
 
C-reactive protein (CRP) 
§ Daily 
  
Admission values 
§ Body temperature, arterial pH and 
base excess (BE) 
  
Highest values (only first 48 h) 
§ Plasma sodium, potassium, 
glucose 
  
Lowest values (only first 48 h) 
§ Plasma sodium, glucose, MAP, 
body temperature, arterial pH and 
BE 
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than 20 who had succumbed within 48 
hours from admission and were 
admitted to burn centre more than 36 
hours after injury. The following 
parameters were collected for the 
enrolled patients: Age, sex, burn 
mechanism, TBSA%, length of ICU 
stay, pre-existing co-morbidities 
(chronic cardiac-, pulmonary, hepatic, 
renal or neurological illness, excl. 
arterial hypertension), sepsis 
(mentioned in medical records),  
inhalation injury, patient intubated on 
arrival, need of escharotomies or 
fasciotomies, ABSI score (Tobiasen et 
al. 1982), Baux score (S. Baux), 
modified Baux score (Osler et al. 
2010), AKI, rhabdomyolysis and need 
for RRT.  
 
4.3 RRT study (IV) 
 
All burn patients who received RRT in 
Helsinki Burn Centre between 
November 1988 and December 2015 
were enrolled. All patients discharged 
from the burn unit were followed up 
until 31st December 2016. The 
following parameters were collected: 
Age, sex, burn mechanism, TBSA%, 
hospital stay time, pre-existing co-
morbidities, sepsis , rhabdomyolysis, 
inhalation injury, Baux score (S. Baux) 
and ABSI score (Tobiasen et al. 1982). 
RRT records after discharge were 
collected from the Finnish Registry for 
Kidney Diseases (FRKD), a registry 
maintained by the Finnish Kidney and 
Liver Association (Finnish Registry for 
Kidney Diseases). This registry covers 
up to 98 percent of patients receiving 
RRT for over three months in Finland. 
The patients’ causes of death (COD) 
were collected from The Causes of 
Death Registry maintained by The 
Statistics Finland (The Causes of 
Death Registry – Statistics Finland). 
The patients’ COD or need for long-
term RRT were recorded at 31st 
December 2016. COD was classified 
via the International Classification of 
Diseases (ICD-10) system by the 
World Health Organization (WHO). 
Some patients’ COD were classified 
via the former ICD-9 system; these 
diagnoses were transformed into 
corresponding ICD-10 codes.  
 
4.4 Statistical analyses in studies I-
IV 
 
Study I-II 
 
Student’s t-test was used for 
continuous variables in the NGAL 
study (I) and the Mann Whitney-U test 
in the BNP study (II) Chi-square or 
Fischer’s Exact Test was used for 
dichotomous variables in both studies 
(I-II). Friedman analysis of variance 
(ANOVA) was used for repeated 
values, and the Wilcoxon Matched 
Pairs test was used post hoc (II). A 
multivariable regression analysis was 
performed for several variables to 
investigate which of them affect NT-
proBNP values (II). The AUC of three 
biomarkers in predicting AKI was 
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determined by the receiver operating 
characteristic (ROC) method (I). 
 
Study III 
 
Student’s t-test was applied for 
continuous variables and chi-square or 
Fischer’s Exact Test for dichotomous 
variables.  A multivariable regression 
analysis was applied for several 
variables to determine their impact on 
AKI development or death during an 
ICU stay. The adjusted model for Baux 
score in predicting death included sex, 
inhalation injury and pre-existing co-
morbidities. AUC for Baux, modified 
Baux and ABSI in predicting death 
were determined by the ROC method. 
 
Study IV 
 
Student’s t-test was used for 
continuous variables and chi-square or 
Fischer’s exact test for dichotomous 
variables. A Kaplan-Meier estimator 
was created to estimate cumulative 
survival after discharge from the burn 
unit. 
 
Studies I-V results were analyzed by 
IBM SPSS Statistics for Macintosh, 
Version 22.0 (Armonk, NY, USA, IBM 
Corp.) (I, III-IV) and by STATA, Version 
12.0 (Stata Corp. LP College Station, 
TX, USA) (II-III). In all studies a p-value 
less than 0.05 was considered as a 
statistically significant difference. 
 
  
4.5 The standard burn care (I-IV) 
 
Patients in all four studies received 
standard burn care regardless of the 
study protocol: Resuscitation mainly by 
RL by the Parkland formula (4ml/kg x 
TBSA%), no colloids during the first 
eight hours. Vasopressors were used if 
fluid resuscitation itself was insufficient 
to maintain adequate hemodynamics. 
Bronchoscopy was performed at an 
early stage when inhalation injury was 
suspected. Operations were 
performed at appropriate times 
regardless of the ongoing studies. 
Preventive escharotomies or 
fasciotomies were performed when 
necessary. RRT was initiated when a 
patient was evaluated to benefit from 
treatment and directional guidelines to 
initiate RRT were met. However, the 
decision to initiate RRT was evaluated 
on an individual basis and not by 
meeting certain criteria. The general 
guidelines to consider RRT initiation 
were: Hyperkalemia (plasma 
potassium >6.5), severe acidosis 
(arterial pH < 7.15), diuresis < 200 
ml/12 h, fluid retention with anuria 
including extremity swelling, 
pulmonary oedema, increased intra-
abdominal pressure, plasma urea > 35 
mmol/l or SCr > 500 μmol/l (5.7 mg/dl).  
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4.6 Definitions for AKI and 
rhabdomyolysis in studies I-IV 
 
Study I and II 
 
AKI was classified if AKIN stage I 
criteria were met (Mehta et al. 2007).  
 
Study III  
 
AKI was classified if SCr rose above 
120 μmol/l, but this was not considered 
to be AKI if it decreased below 120 
μmol/l within 48 hours from the first 
value.  
 
Rhabdomyolysis was classified as a 
plasma CK value ≥ 5000 IU (Sharp et 
al. 2004) 
 
Study IV 
 
Rhabdomyolysis was classified as a 
plasma CK value ≥ 5000 IU (Sharp et 
al. 2004) 
 
Studies I, III-IV 
 
Onset of AKI was classified as “early” 
when encountered within five days 
post burn and “late” after day five 
(Holm et al. 1999). 
 
4.7 Ethical considerations 
 
Studies I and II were approved by the 
Research Ethics Board of Helsinki 
University Hospital (HUH). Studies III 
and IV were waived by the ethics board 
due to the nature of the study (study 
material focused only on medical 
records). Studies I-IV received a 
research permit from HUH.  
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5. RESULTS  
 
5.1 NGAL and NT-proBNP study (I-II) 
 
Nineteen patients treated between Mar 
2013 and Sep 2014 in Helsinki Burn 
Centre were enrolled. Nine patients 
(47.4 %) developed AKI during the 
study period, and two patients needed 
RRT (10.5%) during their hospital stay. 
AKI was diagnosed in five patients via 
SCr alone, in three via UO alone and in 
one patient by both criteria. Both RRT 
patients survived, and their kidney 
function recovered. Two patients 
(10.5%) succumbed during their ICU 
stay: both had AKI and simultaneous 
MOF. Table 6 presents the patients’ 
demographic data. AKI patients had a 
significantly higher BMI, SOFA-score 
at admission and higher SOFA scores 
during the first 7 days of their ICU stay.  
 
SCr and CysC were significantly higher 
at all measuring points (except SCr at 
arrival and at 48h and CysC at arrival 
and 12h) in the AKI group vs. in the 
non-AKI group. NGAL was significantly 
higher in the AKI group only at days 4 
and 5 compared to the non-AKI group. 
Figure 5a-c shows the concentrations 
of these three biomarkers after burn 
injury. The ROC-method’s diagnostic 
power for AKI resulted in AUC of 0.919 
for SCr, 0.866 for CysC and 0.623 for 
NGAL in predicting AKI (Figure 4). 
Plasma NGAL rose on average 72 ± 29 
h (95% CI) later compared to SCr and 
36 ± 43 h later than CysC in patients 
with early AKI using cut-off-points of 
100 μmol/l for SCr, 1,4 mg/l for CysC 
and 400 ng/ml for NGAL. Plasma 
NGAL levels rose a week earlier than 
SCr levels in one late AKI case. When 
using a lower cut-off-point for plasma 
NGAL, 150 ng/ml (as recommended by 
the manufacturer of Triage® meter), 
the time gap of SCr and NGAL 
narrowed to 6 ± 20h (95% CI), but SCr 
was still superior to NGAL in most 
cases. This lower cut-off-point, 
however, resulted in 9/10 non-AKI 
patients having a false diagnosis of 
AKI (plasma NGAL over 150 ng/ml). 
Optimized cut-off-points for all 
biomarkers were 75 μmol/l for SCr, 
0.95 mg/l for CysC and 152 ng/ml for 
NGAL, resulting in sensitivities of 80%, 
85% and 60% and specificities of 84%, 
80% and 53%, respectively.  
All patients received at least 
90% of the suggested resuscitation 
volume determined by the Parkland 
formula during the first 24 hours. The 
AKI group had significantly lower 
minimum BE and arterial pH during the 
first 48 hours. Table 7 presents the 
patients’ resuscitation data of patients. 
NT-proBNP levels increased in all 
patients during the seven-day study 
period (Figure 6); a wide variation was 
observable among single patients 
(Figure 7) and even greater variation 
was observed in the AKI group (Figure 
8).  A linear association emerged 
between NT-proBNP and cumulative 
infusions given on a group level, but 
the association was nonsignificant in 
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the AKI group. A logistic regression 
model (Table 8) was performed with 
several parameters and NT-proBNP by 
explorative fashion, which showed a 
significant association with age, BMI 
and arterial pH at admission with NT-
proBNP values. 
 
 
Table 6 Characteristics and baseline parameters of patients at studies I and II.  
  
Variable 
  
Non-AKI (n=10) 
  
AKI (n=9) 
  
p 
Age 48.2 ± 18.8 59.7 ± 12.4 0.14 
Male sex 5 (50%) 6 (67%) 0.46 
BMI 24.3 ± 2.9 35.7 ± 10.4 0.011* 
Number of co-morbidities 1.1 ± 0.88 1.9 ± 1.76 0.25 
%TBSA 37.6 ± 21.4 45.6 ± 12.5 0.34 
Burn mechanism (Flame:Steam) 10:0 8:1 0.28 
Inhalation injury 4 (40%) 2 (22%) 0.7 
Intubated on arrival 4 (40%) 5 (56%) 0.5 
Need for ventilation 5 (50%) 5 (56%) 0.81 
ABSI scoring 8.5 ± 2.4 10.6 ± 2.0 0.059 
SOFA scoring on arrival 4.2 ± 2.9 7.8 ± 2.3 0.015* 
Highest SOFA score 7.1 ± 3.0 10.8 ± 2.6 0.018* 
Escharotomies needed 6 (60 %) 6 (67%) 0.76 
Duration of ICU time 21.6 ± 10.4 34.9 ± 21 0.107 
Need of RRT 0 (0%) 2 (22%) 0.12 
Non-survivors 0 (0%) 2 (22%) 0.12 
Grading of AKI       
            AKIN 1   2 (22.2%)   
            AKIN 2   3 (33.3%)   
            AKIN 3   4 (44.4%)   
Type of AKI       
           Early AKI   8 (88.9%)   
           Late AKI   1 (11.1%)   
        
ABSI, Abbreviated Burn Severity Index; AKI, acute kidney injury; AKIN, acute kidney injury network; BMI, body mass index; 
ICU, intensive care unit; RRT, renal replacement therapy; SOFA, Sequential Organ Failure Assessment; TBSA, total body 
surface area. Data are reported as mean ± SD or percentage, when appropriate.                                                     
*Statistically significant difference (P< 0.05)                                      
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Table 7 Resuscitation & laboratory data 
                                                                                                            
 All Non-AKI AKI P value 
Patients, n 19 10 (53) 9 (47)  
Parkland, mL 13824 (8400-17280) 8680 (6600-11700) 15360 (14208-17280) 0.01 
Infusions day 1, mL 21587 (16406-32031) 18300 (15436-23054) 32031 (18957-35741) 0.04 
Parkland, ratio* 1.61 (1.23-2.10) 2.04 (1.23-2.34) 1.56 (1.23-1.97) 0.30 
Urine output day 1, mL 1751 (810-2745) 1951 (1140-2760) 1338 (405-2525) 0.27 
MAP on arrival, mmHg 89 (78-100) 93 (78-103) 86 (79-93) 0.40 
Lowest MAP, mmHg 58 (52-63) 58 (57-63) 57 (49-59) 0.24 
CRP on arrival, mg/L 4 (3-9) 4 (3-63) 6 (3-8) 0.90 
Highest CRP, mg/L 239 (198-277) 267 (198-277) 235 (210-264) 0.55 
BE on arrival, mmol/L -5 (-10 to -3) -6 (-9 to -3) -5 (-15 to -4) 0.50 
Worst BE, mmol/L -10 (-13 to -5) -7 (-10 to -4) -13 (-18 to -11) 0.008 
Arterial pH, on arrival 7.3 (7.2-7.3) 7.3 (7.2-7.3) 7.3 (7.2-7.4) 0.97 
Arterial pH, lowest 7.2 (7.1-7.2) 7.2 (7.2-7.2) 7.1 (7.0-7.2) 0.002 
Data are presented as median (25th and 75th quartiles), or n (%). *The ratio between calculated Parkland (4 ml) and 
given infusions on day 1. P-value is calculated between AKI and non-AKI patients. BE, Base excess; CRP, C-reactive 
protein; MAP, Mean arterial pressure.  
 
Figure 4 ROC-curves for three biomarkers in predicting AKI during first week at ICU.
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Figure 5a Changes in SCr during first week at the ICU. Timepoint indicates mean value and 95% CI.  
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Figure 5b Changes in CysC during first week at the ICU. Timepoint indicates mean value and 95% CI.  
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Figure 5c Changes in NGAL during first week at the ICU. Timepoint indicates mean value and 95% CI.  
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Figure 6 The increase of plasma NT-proBNP over time during the first week after admission was significant (ANOVA Chi 
Square = 40.69, P <0.001), post hoc analysis showed p values <0.001 between all time periods except between day 1 and 2 
(p= 0.01) and between days 3-4 and 5-7 (p= 0.049) (not adjusted for repeated measures). Median, box = 25th to 75th 
quartiles, whisker = non-outlier range. 
 
 
Figure 7 Plasma concentration of NT-proBNP maximum value of each patient at different intervals after injury: 12-24 hours, 
36-48 hours, day 3-4, and day 5-7. Black lines = patients with AKI, grey lines = non-AKI. 
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Figure 8 Plasma concentration of NT-proBNP over time by the groups of patients who developed AKI (black bars) and not 
(white bars). Median, box = 25th to 75th quartiles, whisker = non-outlier range. 
 
 
 
 
Table 8 Multivariable regression for plasma concentration of NT-proBNP during the first week after burn 
 
  Coefficient SE p value 95% CI 
TBSA% 3.4 2.0 0.09 -0.5 to  7.2 
BMI -14.4 3.9 <0.001 -22.0 to -6.8 
Age, years 3.6 1.8 0.04 0.1 to 7.0 
Sex, male  -30.3 52.1 0.56 -132.5 to 71.8 
pH at admission -659.3 340.9 0.05 -1327.5 to 9.0 
SOFA, highest  12.7 10.4 0.23 -7.8 to 33.1 
CRP, highest 0.4 0.3 0.15 -0.2 to 1.1 
Cumulative infusions 0.003 0.001 0.01 0.0 to 0.0 
AKI 72.2 78.4 0.36 -81.5 to 225.8 
Constant 4692.7 2494.0 0.06 -195.5 to 9580.9 
Multivariable regression for panel data. Model (between) R2 0.68, P<0.001, patients n=17, recordings n=63. AKI, acute 
kidney injury; BMI, body mass index; CRP, C-reactive protein; SOFA, Sequential Organ Failure Assessment; TBSA, total 
body surface area.  
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5.2 AKI study (III) 
 
Between January 2006 and December 
2015, 1703 patients received 
treatment in the Helsinki Burn Centre. 
187 patients were included to study III 
(Figure 9). 27.3% had AKI and 11.2% 
received RRT during ICU stay. 
Demographic data of all patients 
included are presented in Table 9. 
Based on patients’ medical records, 
none of AKI patients showed evidence 
of pre-existing impaired kidney 
function. AKI patients had significantly 
higher age, TBSA%, ABSI and Baux 
score, longer ICU stay and mortality of 
52.9% vs. 7.4% in no AKI patients. 
Flame burn also seemed to be more 
common in AKI vs. no AKI patients. 
41.2% of AKI patients received RRT 
during their hospital stay. Table 9 
shows demographic parameters 
between AKI and no AKI patients. Two 
thirds of AKI patients had early AKI. 
Late AKI group had significantly higher 
burned TBSA% (57 vs 44) and higher 
ABSI scores (10.6 vs 9.5). All AKIs 
induced by hot air sauna and the vast 
majority of rhabdomyolysis induced 
AKIs (88%) occurred as ‘early’. 75% of 
AKIs caused by hot air sauna needed 
RRT, all of them survived. Table 10 
shows that increasing age and 
TBSA%, sepsis and rhabdomyolysis 
were independent risk factors for AKI 
in a multivariable regression model.  
90.5% of RRT patients were men and 
85.7% of RRT group had early-onset 
AKI. 38.1% of RRT patients received 
CRRT, 42.1% intermittent 
hemodialysis (IHD) and 19% CRRT 
following IHD. AKI patients receiving 
RRT had significantly more 
rhabdomyolysis (33.3%) compared to 
AKI patients not receiving RRT (3.3%).  
Age, TBSA%, ABSI, Baux score or 
mortality did not differ significantly 
between RRT patients and AKI 
patients not receiving RRT. In 37% of 
AKI patients not receiving RRT, a 
decision to withhold RRT in all 
circumstances existed, of these 64% 
succumbed. In 78% of nonsurvivors in 
AKI patients not receiving RRT had a 
decision to withhold RRT in all 
circumstances or their condition was 
too poor to initiate RRT.  
19.8% of all ICU patients 
(n=187) succumbed during their 
hospital stay. Table 11 presents the 
parameters of survivors and 
nonsurvivors. A significant difference 
between survivors and nonsurvivors in 
the AKI group did not emerge in ABSI 
or Baux score. Among RRT patients, 
nonsurvivors had a significantly higher 
Baux score (108 vs 91). Increasing 
age, TBSA% and AKI were 
independent risk factors in predicting 
death during their hospital stay. 
Coefficients for age and TBSA% 
decreased slightly when multivariable 
regression analysis also included AKI.  
Table 10 presents odds ratios (OR).  
ROC curves showed 0.84 (0.78-0.91, 
95% CI) for Baux score, 0.83 (0.76-
0.90) for modified Baux score and 0.83 
(0.76-0.90) for ABSI score in predicting 
death during a hospital stay (Figure 
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12). LD50 for Baux score was 112 
(Figure 11).  
In all patients the likelihood of 
AKI formed a S-shaped curve as 
plotted with Baux score. The likelihood 
of death rose rapidly after Baux score 
80, especially in flame burns. The 
likelihood of AKI and death at Baux 
score 100 was ~40% and ~30%, 
respectively. At Baux score 70, the 
probability of death was ~30% in AKI 
patients, whereas only ~5% in all ICU 
patients. A linear association between 
Baux score and death emerged in AKI 
patients. The results stayed the same 
when all Baux curves (Figure 11) were 
adjusted with all variables presented in 
Table 10.  
 
 
 
 
 
 
 
Figure 9 Overview of patients. AKI, acute kidney injury; ICU, intensive care unit; RRT, renal replacement therapy; 
TBSA, total body surface area. 
 
All	patients	(n=1703)
Included	(n=187)
No	AKI	(n=136) AKI,		No	RRT	(n=30) AKI,	RRT	(n=21)
Excluded	(n=1516)- <	20-%TBSA-Admission	>36h	from	burn	injury- Non-ICU	patient-Death	within	48h	from	admission
		 55	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 Distribution of survivors and non-survivors in A) all patients B) no AKI patients C) AKI patients D) RRT patients E) 
AKI, no RRT patients. TBSA; Total body surface area 
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Figure 11 Baux score in x-axis and probability in y-axis. Death and AKI in all ICU patients (upper row); probability of death in 
AKI patients and –in patients with flame burn (lower row). Baux score predicting 50% chance for each endpoint (AKI, death) 
is marked with vertical line. Marked area around the curve shows 95 % confidence intervals. AKI, acute kidney injury; ICU, 
intensive care unit.  
 
Figure 12 ROC-curves for ABSI-, Baux- and modified Baux scores predicting death during a hospital stay. ABSI, Abbreviated 
Burn Severity Index. 
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Table 10 Risk factors of AKI and death from multivariate models 
Variable OR (95%CI) for 
AKI 
OR (95%CI) for 
death 
OR (95%CI) for 
death with AKI 
OR (95%CI) for death 
in AKI patients 
Age (per 1y increase) 1.06 (1.03-1.09) 1.07 (1.03-1.10) 1.05 (1.02-1.09) 1.03 (0.99-1.07) 
TBSA (per 1% increase) 1.07 (1.05-1.11) 1.09 (1.06-1.13) 1.07 (1.04-1.11) 1.04 (1.00-1.09) 
Comorbidities 0.88 (0.37-2.09) 0.95 (0.38-2.39) 1.03 (0.39-2.74) NA 
Inhalation injury 2.46 (0.94-6.40) 1.77 (0.66-5.00) 1.33 (0.43-4.06) NA 
Sepsis 6.69 (1.71-26.26) 1.03 (0.26-4.09) 0.51 (0.12-2.19) NA 
Rhabdomyolysis 3.94 (1.10-14.06) 2.55 (0.66-9.83) 1.83 (0.43-7.72) NA 
AKI NA NA 5.97 (2.20-16.20) NA 
 
AKI, acute kidney injury; NA, not available; TBSA, total body surface area.  
 
 
Table 11 Demographic data of non-survivors vs survivors 
    
Variable Survivors (n=150) Non-survivors (n =37) P 
Age 44.3 ± 19.0 (1-84) 54.9 ± 17.4 (14-87) 0.002* 
Burned TBSA 34.2 ± 13.4 (20-84) 49.6 ± 18.5 (20-86) <0.0001* 
Burn mechanism 
        Flame 
        Sauna (hot air) 
        Electrical 
        Liquid 
        Explosion 
        Steam 
 
107 (71.3 %) 
11 (7.3 %) 
11 (7.3 %) 
10 (6.7 %) 
8 (5.3 %) 
3 (2.0 %) 
 
33 (89.2 %) 
1 (2.7 %) 
0 (0 %) 
3 (8.1 %) 
0 (0 %) 
0 (0 %) 
 
0.03* 
ICU stay time (days) 27.3 ± 17.3 (2-95) 17.5 ± 15.5 (3-51) 0.002* 
ABSI-score 7.9 ± 1.6 (4-13) 10.1 ± 1.5 (6-13) <0.0001* 
Baux score 78.6 ± 20.5 (32-141) 104.6 ± 16.0 (59-138) <0.0001* 
Male sex 113 (75.3 %) 26 (70.3 %) 0.53 
Inhalation injury 22 (14.7 %) 10 (27.0 %) 0.09 
Intubated on arrival 69 (46.0 %) 22 (59.5 %) 0.20 
Escharotomies/fasciotomies 78 (52.0 %) 30 (81.1 %) 0.001* 
Pre-existing co-morbidity 52 (34.7 %) 17 (45.9 %) 0.20 
Sepsis 12 (8.0 %) 6 (16.2 %) 0.21 
Rhabdomyolysis 16 (10.7 %) 5 (13.5 %) 0.57 
AKI 24 (16.0 %) 27 (73.0 %) <0.0001* 
RRT 12 (8.0 %) 9 (24.3 %) 0.009* 
    
Data are reported as mean ± SD, (interval) or percentage, when appropriate. ABSI, Abbreviated Burn Severity 
Index; ICU, intensive care unit; RRT, renal replacement therapy; TBSA, total body surface area.  
*) Statistically significant difference, P <0.05. 
		 59	
5.3 RRT study (IV)  
 
Between November 1988 and 
December 2015, 68 patients received 
RRT in the Helsinki Burn Centre. 
Thirty-six patients (52.9%) succumbed 
during their hospital stay. Table 12 
presents all the demographic data of 
survivors and nonsurvivors during their 
hospital stay. None of the RRT patients 
had a pre-existing weakened kidney 
function on admission, according to the 
medical records. The need for RRT 
subsided in 26 patients (81.3% of 
survivors) before discharge, and no 
patient received RRT long-term (> 3 
months) after a primary hospital stay. 
Six patients (18.8%) still required RRT 
at discharge; of these, only two 
patients needed long-term RRT (> 3 
months) after burn center discharge. 
These two patients received RRT for 
10.5 and 17 months before the need 
for RRT subsided. Of these two 
patients, the other patient developed 
CKD within five years and became 
RRT dependent. 56.3% of the 
discharged patients were alive at the 
end of follow-up. The average follow-
up time was 7.4 years (range 5-7622 
days) and 9.3 years (range 367-7607 
days) in those who were alive at the 
end of follow-up. The number of follow-
up years was 238. Figure 13 presents 
the Kaplan-Meier analysis of patients 
surviving after discharge. Five patients 
succumbed to burns during follow-up 
(underlying COD (ICD-10: T20-32.9); 
this occurred within 50 days from 
discharge. One patient died due to to 
CKD (underlying COD ICD-10: N03, 
N18-19), and eight patients 
succumbed due to other reasons. The 
one-year mortality after discharge was 
18.8%; 83% occurred due to burns. 
Figure 14 presents the flow chart of 
patients’ follow-up. 
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Table 12 Demographic data of patients 
     
Variable All patients (n=68) Survived (n=32) Succumbed (n=36) P  
Age 49.0 ± 13.1 (17-76) 47.4 ± 12.7 (19-76) 50.5 ± 13.4 (17-75) NS 
Burned TBSA 43.0 ± 19.2 (7-90) 37.3 ± 17.2 (7-77) 47.9 ± 19.6 (10-90) 0.03* 
Burn mechanism 
        Flame 
        Sauna (hot air) 
        Electrical 
        Liquid 
        Scald 
        Explosion 
        Other 
 
52 (76.5 %) 
6 (8.8 %) 
3 (4.4 %) 
3 (4.4 %) 
2 (2.9 %)  
1 (1.5 %) 
1 (1.5 %)                            
 
22 (68.8 %) 
4 (12.5 %) 
3 (9.4 %) 
1 (3.1 %) 
1 (3.1 %) 
1 (3.1 %) 
0 (0 %) 
 
30 (83.3 %) 
2 (5.6 %) 
0 (0 %) 
2 (5.6 %) 
1 (2.8 %) 
0 (0%) 
1 (2.8 %) 
 
NS 
Hospital stay (days) 36.9 ± 24.8 (2-111) 54.0 ± 20.6 (15-111) 21.7 ± 17.2 (2-65) < 0.001* 
ABSI score 8.7 ± 2.0 (5-14) 8.2 ± 1.8 (5-11) 9.2 ± 2.0 (5-14) 0.04* 
Baux score 91.5 ± 19.1 (46-138) 84.1 ± 17.8 (46-113) 97.8 ± 18.1 (50-138) 0.003* 
Male sex 58 (85.3 %) 26 (81.3 %) 32 (88.9 %) NS 
Inhalation injury 17 (25 %) 9 (28.1 %) 8 (22.2 %) NS 
Pre-existing co-morbidity 25 (36.8 %) 13 (40.6 %) 12 (33.3 %) NS 
Sepsis 25 (36.8 %) 11 (34.4 %) 14 (38.9 %) NS 
Rhabdomyolysis 22 (32.4 %) 9 (28.1 %) 13 (36.1 %) NS 
Early AKI (<5 days) 36 (52.9 %) 25 (78.1 %) 22 (61.1 %) NS 
Non-survivors 36 (52.9 %)    
     
Data are reported as mean ± SD, (range) or percentage, when appropriate. P-values are calculated between survived and 
succumbed patients. ABSI, Abbreviated Burn Severity Index; AKI, acute kidney injury; NS, not significant; RRT, renal 
replacement therapy; TBSA, total body surface area. *) Statistically significant, P <0.05 
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Figure 13 Kaplan-Meier analysis of patients’ survival after discharge. 
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All	RRT	patients	(n=68)
Succumbed	(n=36) Discharged	(n=32)
RRT	ended	until	discharge	(n=26)
Alive	(n=16) Dead	(n=10)
Death	due	to	burns1 (n=2) Death	for	any	other	cause*	(n=8)
RRT	after	discharge	(n=6)
RRT	>	3	months	(n=2)
Alive	(n=1) Dead	(n=1)
Death	due	to	kidney	failure2
RRT	<	3	months	(n=4)
Alive	(n=1) Dead	(n=3)
All	deaths	due	to	burns1
Figure 14 Flow chart of patients’ survival 
 
1) ICD-10: T20-32.9 2) ICD-10: N03, N18-19 *) COD not related to burns or kidney failure. 
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6 DISCUSSION 
 
6.1 Main findings 
AKI was relatively common among 
critically ill burn patients, and it notably 
increased the mortality. Plasma NGAL 
rose in nearly every patient during the 
first week after admission to the ICU. 
NGAL failed to rise in patients with AKI 
before a rise was seen in SCr, except 
in one patient with late AKI. Plasma 
NGAL rose over time by the end of the 
study period, and a rise was seen in 
nearly all patients having AKI or not. A 
diagnostic value of three biomarkers 
measured by the ROC method showed 
NGAL had a notably lower value than 
SCr or CysC (I).    
Plasma NT-proBNP showed a positive 
correlation to cumulative infusions and 
older age but also a negative 
correlation with the body mass of the 
patients in a multivariable regression 
model. A great variation existed 
between single patients in absolute 
values of NT-proBNP. An association 
between AKI and NT-proBNP was not 
observed (II).  27.3% of burn-ICU 
patients developed AKI during their 
stay, and 19.8% died in hospital. 
Patients who died had a more 
extensive burn injury, older age, and 
higher ABSI and Baux score. 73% of 
nonsurvivors had AKI. Age and 
TBSA% were independent risk factors 
for death during an ICU stay. AKI 
increased the risk of death to nearly 6-
fold in multivariable regression 
analysis. ABSI, Baux and modified 
Baux score at arrival nearly equally 
predicted death during an ICU stay. 
Age, TBSA%, rhabdomyolysis and 
sepsis were individual risk factors for 
AKI during ICU stay. A difference in 
outcome could not have been provided 
between early and late AKI patients 
(III). The need for RRT had subsided at 
discharge phase in 81.3% of patients 
who underwent RRT during ICU stay 
and were discharged. Of those whose 
need for RRT continued after 
discharge, 67% needed RRT for less 
than 6 months. COD was potentially 
related to the AKI encountered during 
acute ICU stay in one patient during 
follow-up. The linkage of these two 
aspects remained unknown (IV) due to 
the long follow-up time and events 
occurring between discharge and 
death. 
6.2 Plasma NGAL in AKI 
diagnostics (I) 
The results show that a constant rise in 
plasma NGAL on a group level could 
be observed during the first week at the 
ICU (Figure 5c).  
The AKI classification in study I (AKIN, 
UO or SCr) is problematic due to SCr 
being one of the criteria for AKI that 
involves a major risk for circular 
reasoning. Although this risk exists, we 
expected NGAL to react faster than 
SCr in developing AKI. NGAL failed to 
diagnose AKI before SCr on an 
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individual level, except in one late AKI 
case that occurred on the 14th post-
burn day. In Figure 4 plasma NGAL 
shows a poor AUC determined by the 
ROC method compared to SCr and 
CysC in AKI diagnostics. The number 
of participants was limited, so it was 
impossible to evaluate the diagnostic 
power of three biomarkers on certain 
timepoints with sufficient statistical 
power. Otherwise, more information 
would have been provided about their 
use in primary diagnostics.  
Our findings were mainly opposite to 
those in previous papers published on 
the same subject, though it must be 
noted that these studies contain 
inconsistencies in their designs and 
participants. A study of 22 burned 
children showed that NGAL was 
significantly elevated compared to SCr 
at day one and day five in patients who 
developed AKI as defined by the 
RIFLE criteria. 83% of AKI patients in 
that study had a mild AKI (RIFLE: 
Risk), and only one patient was 
classified as “Injury.” Moreover, 91% of 
the patients had scald injuries. All 
patients had recovered kidney function 
within a few days after their arrival 
(Yavuz et al. 2014). Study I included 
only one patient aged < 18 years 
(5.3%), and nearly all patients (94.7%) 
in study I had flame injuries. Flame 
burns often deepen and extend the 
burn injury and also pose the risk of 
inhalation injury (Aldemir et al. 2005). 
These factors perhaps cause the 
tendency for NGAL levels to rise due to 
nonrenal causes (Chun et al. 2017).    
A study of 30 burned adults showed 
that NGAL was significantly elevated in 
AKI vs. non-AKI patients 4, 12 and 24 
hours after admission, whereas SCr 
did not differ between groups. NGAL 
had also a better AUC in predicting AKI 
4 hours after injury as defined by 
RIFLE criteria (Sen et al. 2015). The 
determination point for AUC was 4 
hours after admission, and the 
researchers’ definition of AKI met at 
least the criteria of “Injury” as defined 
by RIFLE (Table 1). SCr is problematic 
in the early phase of AKI diagnostics, 
because it is known to react slowly to 
rapidly deteriorating kidney function 
(Nguyen & Devarajan 2008). Despite 
the study having a similar study 
population to our study I, the results 
differed notably between the two 
studies. A potential explanation for that 
is that the definition of AKI differed 
between studies: The definition used in 
study I allowed diagnosing AKI with 
milder criteria than Sen et al did (Sen 
et al. 2015). One aspect is also 
hemodilution, which was not taken into 
account. A great volume of infusions 
decrease SCr values and interrupt 
measuring.    
The largest study on this subject (90 
patients) showed that NGAL had better 
AUC in predicting early AKI (onset < 5 
days) development on arrival and three 
and six hours from injury, whereas SCr 
was more accurate at 12, 24 and 48 
hours from injury. AKI was defined by 
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RIFLE criteria. Both SCr and NGAL 
were poor in predicting late AKI 
development. Results showed that the 
accuracy of SCr in predicting early AKI 
increased towards 48h after arrival, 
whereas the accuracy of NGAL tended 
to decrease (H. T. Yang et al. 2014). 
This possibly suggests that levels of 
NGAL increase over time in all burn 
patients, which enhances the risk for 
false positive results in patients not 
having AKI.  
A small study of 15 burned adults 
concluded that NGAL was significantly 
more elevated in AKI patients 48 hours 
after injury compared to non-AKI 
patients, whereas the same thing was 
not observed with SCr. However, they 
also noted that levels of NGAL tended 
to increase from arrival in all burn 
patients, whether or not the patients 
had AKI (Howell et al. 2015). We 
observed the same effect in study I.  
A study of 45 burned adults with >20% 
burned TBSA showed NGAL 
significantly elevated compared to SCr 
in day one, three and seven after burn 
injury. Plasma NGAL on day seven 
was the best predictor for AKI 
development (Hong et al. 2013). 
Nearly all AKIs (89%) were classified 
as “early” in study I, whereas in that 
study all AKIs were classified as “late.” 
Over 70% of those AKI patients died, 
and the most common COD was MOF 
accompanied by sepsis. Both of these 
are conditions with systemic 
inflammation, a potential source of 
extra-renal NGAL.  
Previous publications have shown that 
NGAL is a potential biomarker after 
severe burn injury, and they highlight 
NGAL as superior to SCr in AKI 
diagnostics. NGAL is represented in 
three forms in the human body, and 
these forms cannot be distinguished 
with current POC devices (Legrand et 
al. 2014; Mårtensson & Bellomo 2014). 
This problem, which has not been 
brought up in previous publications, is 
also present in study I. A more recent 
paper highlights burned TBSA%, 
systemic inflammation and sepsis as 
confounding factors for rises in NGAL 
levels (Chun et al. 2017). The study of 
76 patients noticed NGAL to be 
elevated also in those who did not 
develop AKI. Study I also observed 
this.  
A study of 84 subjects investigated 
diagnostic performance of plasma 
NGAL compared to SCr one to five 
weeks after burn injury. It concluded 
that SCr was more accurate in 
predicting AKI development during the 
first week compared to plasma NGAL. 
The diagnostic performance of SCr 
decreased at measuring points week 
two to five, while performance of NGAL 
remained poor throughout the study. 
The study also showed that NGAL rose 
parallelly in both AKI and non-AKI 
patients during the first week after burn 
injury, with nearly equal concentrations 
on a group level (Y. Kim et al. 2018). 
Study I also observed this aspect 
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(Figure 5c). High NGAL on arrival 
predicted later development of a major 
kidney event in a recent cohort of 87 
burn patients (Dépret et al. 2018). 
Patients who underwent RRT showed 
high NGAL levels (>980ng/ml) in study 
I. This potentially suggests that NGAL 
of renal origin represents tubular injury 
and has potential in AKI diagnostics if 
confounding extra-renal sources of 
NGAL can be ruled out. 
 
Impairment of renal function was not 
observed even though NGAL levels 
constantly rose over time, and in nearly 
all patients the cut-off-point of 150 
ng/ml was achieved. Two patients 
even exhibited NGAL levels of 
>600ng/ml. This may suggest that 
current laboratory diagnostic 
equipment cannot reliably measure 
renal NGAL levels in severely burned 
patients. It remained unknown which 
isoforms of NGAL were detectable with 
the used POC device (Alere Triage®). 
We could not conclude that NGAL 
levels rose faster than SCr in patients 
who developed AKI. This validates our 
findings.  
6.3 Plasma NT-proBNP in AKI 
diagnostics and its behaviour 
during acute fluid resuscitation 
(II) 
Study II’s population was the same as 
study I’s, 19 consecutive patients 
treated in Helsinki Burn Centre 
between 2013-2014.  A constant rise 
on a group level was observed after 
repeated measurements of NT-
proBNP during the first week after burn 
injury. A greater variance was seen 
among AKI patients (Figure 8). A 
multivariable regression analysis 
revealed that changes in NT-proBNP 
correlated with cumulative infusions 
adjusted for variables presented in 
Table 8. We also noticed correlation 
with respect to older age and lower 
BMI. The reference values of NT-
proBNP take into account the age of 
the patient and therefore vary in 
different age groups (Maisel et al. 
2008). High levels of NT-proBNP have 
also been observed in low BMI non-
cardiac patients (T. J. Wang et al. 
2004). We observed the same effect in 
study II. This effect is thought to be 
related to fat tissue’s ability to 
breakdown circulating NT-proBNP 
(Sarzani et al. 1996). No association 
was observed between AKI and higher 
NT-proBNP; however, this aspect 
remained unclear, most likely due to 
the small sample size.  
High concentrations of NT-proBNP 
were detected in two patients (Figure 
7). Of these, one had pre-existing atrial 
fibrillation, and the other needed RRT. 
Both are conditions in which the 
patient’s ability to tolerate great 
amounts of volume intake is restricted. 
Accordingly, this causes stressed 
volume increase (Spiegel 2016) and 
thus possible secretion of NT-proBNP 
into the circulation due to increased 
stretch of the cardiac muscle 
(Ruskoaho 1992). We noticed 
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variations between patients in 
circulating levels of NT-proBNP 
(Figure 7), which possibly indicates 
that individual tolerance to volume load 
has an essential role in NT-proBNP 
secretion. In addition, capillary leakage 
and systemic vasodilatation caused by 
systemic inflammation at an early 
stage after burn injury results in a 
decrease in cardiac peptide secretion 
(deLeeuw et al. 2011, deLeeuw et al. 
2016). Based on recent evidence and 
our findings, several parameters and 
the clinical situation affect circulating 
NT-proBNP values. Based on these 
findings, NT-proBNP might be a 
beneficial biomarker in guiding fluid 
resuscitation after burn injury. 
However, a larger sample size and 
comprehensive consideration of 
confounding factors are mandatory 
before NT-proBNP can be utilized 
routinely in clinical practice.  
6.4 Incidence of AKI in severe 
burns (III) 
Study III included 187 patients, 
retrospectively collected, treated in the 
Helsinki Burn Centre between 2006 
and 2015.   
 Study III concluded the 
incidence of AKI to be 27.3% and an 
overall mortality of 19.8%. Table 2 
shows the range in the incidence of 
AKI between earlier studies. The type 
of patients included and the definition 
of AKI are the most likely causes for 
this observation. Over 20 different 
definitions for AKI have been 
presented during the past decades 
(Brusselaers et al. 2010). This makes 
it impractical and even impossible to 
compare studies with each other 
unless they have similar patient 
cohorts and definitions of AKI.  
Elevated SCr levels are common 
among the burn population on arrival at 
the ICU (Yim et al. 2015).  Thus, by 
using an absolute value of 120 μmol/l 
(1.4 mg/dl) as a definition for AKI 
instead of a percentage-based rise, we 
had a higher sensitivity for the 
diagnosis of AKI in study III. In study III, 
over a third of AKI patients (37%) 
showed SCr > 100 μmol/l (1.1 mg/dl) 
on ICU arrival, which makes AKI 
diagnostics challenging when using 
percentage-based classifications, as 
Table 1 shows. However, using SCr in 
AKI diagnostics is known to be 
impractical in rapidly progressing AKI 
(Nguyen & Devarajan 2008). A recent 
American cohort of 1040 ICU burn 
patients, in which AKI was defined by 
AKIN (without diuresis criterion), 
showed that a majority of patients 
developed AKI (58%). This definition 
for AKI and their study design is one of 
those closest to study III. A vast 
majority of patients in this American 
study had mild AKI, which resulted in 
moderate mortality. These findings 
indicate that many patients with major 
burn injury have a transient SCr rise 
that subsides rapidly. Study III also 
observed this trend. The proportion of 
patients having AKI increased along 
with increase in TBSA%, likewise 
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shown in Figure 10.  
6.5 The use of RRT to improve 
outcome (III) 
Twenty-one patients received RRT in 
study III (41.2% of AKI patients) 
between 2006 and 2015. The number 
of patients receiving RRT has stayed 
minor over the years (~2.5 patients per 
year). A significantly greater proportion 
of RRT patients were males in study III, 
and rhabdomyolysis was more 
common compared to the rest of the 
AKI patients (Table 9). Study III’s RRT 
patients had reduced mortality 
compared to the rest of the AKI 
patients; however, this difference (43% 
vs. 60%) did not reach statistical 
significance. The mortality of RRT 
patients has decreased from 63% to 
43% (Mustonen & Vuola 2008) in 
comparison with the earlier study from 
the Helsinki Burn Centre; therefore, we 
could have expected the groups to 
have a significant difference in 
mortality in study III. The most likely 
reason for this is the limited sample 
size. A major confounding factor in 
estimating the protective effect of RRT 
is that 37% of AKI patients who did not 
receive RRT had a decision made to 
withhold RRT in all circumstances. Of 
these, 64% succumbed during their 
ICU stay. The decision not to initiate 
RRT has potentially added to the poor 
outcome of these patients. It is likely 
that most of them had such a poor 
prognosis of survival that they would 
not have benefited from RRT. Making 
strong conclusions about the 
usefulness of RRT initiation to reduce 
mortality is limited by this biased 
patient selection. As the study was not 
a randomized, controlled trial, study III 
cannot reliably evaluate the effect of 
RRT. 
6.6 Risk factors for AKI and death 
during ICU stay (III) 
Table 10 shows that study III 
concluded that increasing age, 
TBSA%, sepsis and rhabdomyolysis 
were independent risk factors for AKI 
development during an ICU stay. 
However, due to the small sample size, 
confidence intervals were very wide 
except for age and TBSA%. Therefore, 
study III merely reflects previous 
evidence when rhabdomyolysis and 
sepsis increased the risk for AKI 
development (Wu et al. 2016; Stewart 
et al. 2013). The ORs for age and 
TBSA in predicting AKI were on the 
same scale as shown in previous 
evidence among severely burned 
patients (Clemens et al. 2016; Queiroz 
et al. 2016). Study III could not verify 
other risk factors for AKI development, 
because the lack of a sufficient number 
of patients limited performing a more 
extensive multivariable regression 
analysis.  
The proportion of inhalation injury was 
significantly higher in the AKI vs. no 
AKI group (Table 9), but multivariable 
regression analysis failed to 
demonstrate it as a risk factor for AKI 
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(Table 10). This is assumed to be due 
to the small sample size, because an 
earlier pooled analysis has confirmed 
inhalation injury as a risk factor for AKI 
(Wu et al. 2016).  
Pre-existing medical conditions had no 
association with AKI development or 
death in study III. Two earlier studies of 
burn patients concluded that pre-
existing medical conditions did not 
increase the risk of death, and co-
morbidities were not more common in 
AKI patients compared to patients 
without AKI (Palmieri, Lavrentieva & 
Greenhalgh 2010b; Pompermaier et al. 
2015). A more extensive American 
study concluded that pre-existing 
conditions increased the risk of death. 
However, the impact varied depending 
on the type of illness (Thombs et al. 
2007). Study III did not take into 
account any coefficienting for pre-
existing conditions. Table 10 shows 
increasing age, TBSA% and AKI as 
individual risk factors for death.  
Flame burn was over-represented in 
nonsurvivors vs. survivors (Table 11). 
Earlier evidence has shown flame 
burns over-represented in 
nonsurvivors, likely due to the nature of 
flame burn injuries being more severe 
and having a high probability of 
causing inhalation injury (Aldemir et al. 
2005; Mustonen & Vuola 2008).  
Conflicting evidence exists about the 
effect of female sex with respect to the 
outcome after burn injury (Coca et al. 
2007; McGwin et al. 2002; Queiroz et 
al. 2016). A larger Swedish study of 
1119 individuals did not find sex having 
an effect on mortality (Steinvall et al. 
2011). An American cohort study 
concluded that females aged <60 
years had increased risk for death, 
whereas older women did not (McGwin 
et al. 2002). Another American study 
repeated these findings and concluded 
that females aged 30-59 years had an 
increased risk for death (O'Keefe et al. 
2001). It must be emphasized that 
study III included only 48 women, 
which limits making strong conclusions 
from this study. 
Figure 10 shows a notable increase in 
mortality in patients with co-existing 
AKI when evaluating the overall 
unadjusted effect of AKI to increase 
mortality. The mortality stays around 
~40% (TBSA 20-30%), ~50% (TBSA 
31-50%) and ~65% (TBSA >50%), 
whereas corresponding proportions in 
the same groups without co-existing 
AKI were ~5%, ~7% and ~30%, 
respectively.  
6.7 Early vs. late AKI and outcome 
(III) 
No strong evidence of reduced 
mortality was shown among early AKI 
patients (onset within five days from 
admission) compared to late AKI 
patients. A circulation deficit and a lack 
of oxygen to the kidneys plays a role in 
early AKI, whereas late AKI is usually 
a part of MOF with limited treatments 
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available (Holm et al. 1999). Early 
studies have concluded that early 
onset AKI is associated with better 
outcomes than late onset AKI (Aikawa 
et al. 1990, Davies et al. 1994), but 
contrary evidence has surfaced since 
then (Mustonen & Vuola 2008; Holm et 
al. 1999; Witkowski et al. 2016; 
Schneider et al. 2012; Mosier et al. 
2010). However, these studies, have 
different definitions for early and late 
onset AKI and also for AKI itself, which 
makes it impossible to compare them 
with each other, thus limiting their 
usefulness in this respect. Study III’s 
late AKI patients were significantly 
older and had significantly higher ABSI 
score than the early AKI patients. In 
addition, 50% of early AKI patients 
received RRT, compared with only 
24% of late AKI patients. As mentioned 
earlier in the thesis, AKI patients who 
did not receive RRT had more pre-
existing conditions, and some were 
withheld from receiving RRT. With 
respect to these findings in study III, 
the better outcome of early-onset AKI 
patients can be explained by less 
severe burn injuries, potentially fewer 
pre-existing conditions and perhaps by 
the better-known response of early-
onset AKI to fluid resuscitation and 
other supportive treatments.  
6.8 The prediction of prognosis by 
ABSI, Baux and modified Baux 
score (III) 
Study III showed equal AUC 
determined by the ROC method for 
Baux (0.84), modified Baux (0.83) and 
ABSI score (0.83) in predicting death 
during an ICU stay (Figure 12). Table 
4 shows a variation in Baux score 
between 0.81 and 0.97 AUC in 
predicting death during a hospital stay. 
A Swedish study concluded as high as 
0.97 AUC with 1946 burn patients 
(Pompermaier, Steinvall, Elmasry, et 
al. 2017). In contrast, the modified 
Baux score has shown 0.84-0.98 AUC 
and ABSI score 0.76-0.97 AUC in 
predicting death (Table 4). Study III’s 
results indicate that despite the scoring 
formulas being old and based on 
limited study populations, they are still 
fair predictors for outcome. Our sample 
size was notably smaller than in most 
studies presented in Table 4. This 
increases the possibility of coincidence 
affecting the prediction power. 
However, it can be speculated that the 
decline in prediction can be explained 
through modern advancements in 
critical burn care that results in better 
patient outcomes over time (Akerlund 
et al. 2007). Study III indicated  the 
Baux score 112 as LD50, which has 
improved from earlier decades (LD50 
~100) (Wibbenmeyer et al. 2001; Bang 
& Ghoneim 1996), and it is on the 
same scale with studies conducted 
during the same era (LD50 ~110) 
(Roberts et al. 2012; Steinvall et al. 
2016). These values are remarkably 
higher than those in the early 1960s 
when the Baux score was presented 
(LD50 ~75) (S. Baux). Figure 11 shows 
that the  relationship between Baux 
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score and the probability of death and 
the shape of the curve is comparable 
with earlier evidence (Tsurumi et al. 
2015). The risk of death is small with a 
Baux score <80, but after 80 the risk of 
death increases, and the increase is 
even greater in flame burns. It must be 
noted that flame burn was the 
aetiology of burns in 75% of patients in 
study III. The risk of death increases 
more linearly in AKI patients but is 
notably higher compared to all patients 
with small Baux scores (<80). The LD50 
was 112 in all patients; the 
corresponding number was 96 in AKI 
patients. This highlights that AKI is an 
individual factor for poor outcome.  
6.9 The mortality after need for RRT 
(IV)  
Nearly 53% of patients receiving RRT 
in study IV succumbed during their 
hospital stay. This proportion of 
mortality is notable, but it has 
decreased from earlier studies among 
burn patients who received RRT during 
their hospital stay (Sánchez-Sánchez 
et al. 2016; Holm et al. 1999; Leblanc 
et al. 1997). One-year mortality after 
discharge was 19% in study IV, which 
is comparable with general ICU 
patients having received RRT during 
their ICU stay (De Corte et al. 2016). 
However, mortality is higher than in 
burn patients not receiving RRT in the 
ICU setting (Pavoni et al. 2010).  
 83% of deaths during the first 
year were due to burns (underlying 
COD, ICD-10: T20-32.9), all of which 
occurred within 50 days from 
discharge. CODs of these events were 
similar to those who died during a 
hospital stay. The most common 
CODs were pneumonia (ICD-10: J12-
18.9) and ARDS (ICD-10: J80). During 
the entire follow-up, over half of the 
deaths (8/14, 57%) were caused by 
nonrenal or nonburn aetiology. Over 
half of these deaths occurred due to 
cardiovascular events (ICD-10: I20-
24.9, I60-64). A registry study of 
hospitalized patients has concluded 
that AKI patients had a higher risk for 
later development of cardiovascular 
disease. The risk correlated with the 
severity of AKI (Choi et al. 2010). Two 
other studies have also concluded that 
burn patients have an increased risk 
for a later myocardial infarction (Abu-
Sittah et al. 2012; Thalji et al. 2017). 
 Overall, two registry studies 
found an increased all-cause mortality 
in burn patients after discharge 
compared to matched controls in the 
general population (Duke et al. 2015; 
Mason et al. 2018). Younger age and 
the absence of pre-existing conditions 
predicted good survival after burn 
injury, whereas higher age increased 
the risk of death immediately after 
discharge (Nitzschke et al. 2017; 
Pompermaier, Steinvall, Fredrikson, et 
al. 2017). After reviewing the patients 
who died shortly after discharge (within 
50 days), it was noticed that they were 
discharged at too early a phase after 
their burn injury from the burn unit and 
that in some cases RRT was still in 
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progress. These actions have 
potentially contributed to the poor 
outcome. Finally, the number of 
patients remaining to follow-up was 
small, limiting the ability to make 
conclusions between CODs and AKI.    
6.10 Long-term need for RRT after 
burn injury and RRT (IV) 
The need for RRT continued after 
discharge in six patients (19% of 
survivors). Only in two patients (6% of 
survivors) did the need exceed 3 
months. These patients received RRT 
constantly for 10.5 and 17 months 
before need for RRT subsided (Figure 
14). Study IV showed that burn 
patients receiving RRT had a better 
kidney function recovery rate than in a 
study of general ICU patients receiving 
RRT (De Corte et al. 2016), However, 
in their study, those who remained 
dialysis dependent had an already 
elevated baseline SCr, whereas none 
of the patients in study IV had previous 
kidney dysfunction.  
One patient developed CKD several 
years after initial recovery of kidney 
function. However, this patient 
required health care services not 
related to the burn injury after the initial 
hospital stay due to burns. Linkage of 
the CKD and AKI remained unknown. 
The medical records for this patient 
were assessed, and the 
documentation was deemed 
adequate.  
Only two registry studies to our 
knowledge have evaluated the 
relationship between burn injury and 
long-term impairment of kidney 
function. A Finnish registry study 
concluded that the risk for ESRD 
increased after need for health care 
services due to burns compared to the 
general Finnish population. This study 
kept the linkage of burn injury and 
impairment of kidney function 
plausible, though exact explanations 
remained unknown. Their study failed 
to mention essential factors, such as 
the severity of burn injury, possible 
burn-related AKI or need for RRT 
relating to burn injury; thus, their 
conclusions cannot be extrapolated to 
burn related AKI. The study included 
partly same patients as study IV  
(Helanterä et al. 2016). An American 
registry study concluded burn-induced 
AKI as risk factor for ESRD and for the 
need of chronic dialysis one year after 
injury (Thalji et al. 2017). The 
proportion of dialysis-dependent 
patients one year after injury was 3.8% 
in study IV, whereas an American 
register study found it to be 4.6% 
(Thalji et al. 2017). In a recent 
American cohort of 170 burn patients 
21% of patients received RRT at the 
discharge and 9% after six months; 
corresponding proportions were 19% 
and 6% in study IV, respectively 
(Chung et al. 2018).  
Burn-related AKI or AKI for any other 
reason is potentially an accelerating 
factor for underlying weakened kidney 
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function (acute on chronic), and 
evidence suggests this plausible, even 
with completely normalized SCr after 
AKI in non-burn population (Chawla & 
P. L. Kis immel 2012; Jones et al. 
2012) In conclusion, the later 
worsening of kidney function with this 
one individual patient (who died after 
CKD during follow-up) could have 
been accelerated due to burn-induced 
AKI, but this remained unknown.   
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7. LIMITATIONS 
Studies I and II included only 19 patients, which limited the ability to make strong 
conclusions on certain aspects. We were unable to investigate biomarkers at certain 
time points due to too small a sample size, which would have provided further 
information on their diagnostic power in time to time variation. Current laboratory 
equipment cannot distinguish between the different isoforms of NGAL, so it is 
impossible to say whether the observed rise of NGAL levels in study I is from renal 
aetiology, suggesting tubular injury. We did not measure objective parameters 
describing cardiovascular status by invasive methods in study II.  
The AKI definition in study III differs from many recent studies, and it must be noted 
when results are interpreted. Study III included almost 200 patients, a reasonable 
amount. Nevertheless, an even larger number of patients would have been required 
to reach sufficient statistical power in many subgroup analyses. The low number of 
end points limited conducting a more comprehensive multivariable regression 
analysis. Despite a long study time of ten years, only 21 RRT patients were included, 
and we were unable to provide evidence from RRT and its association to AKI or 
mortality. The selection of patients to receive RRT was biased, and the decision to 
initiate RRT was made on an individual basis rather than by a structured algorithm. 
This had an effect on the outcome. Many patients succumbed who were withheld 
from receiving RRT. It is obvious that many of them would have likely succumbed 
despite RRT, but the decision to withhold RRT has potentially accelerated the poor 
outcome in some individuals.  
We managed to gather only 32 individuals in study IV to perform a follow-up analysis, 
despite the long study period (over 27 years). Although average follow-up time was 
7.4-9.3 years, it remained shortest (a little over a year) in those who were alive at the 
end of follow-up. As seen in study IV, the chronic impairment of kidney function may 
take many years or even decades to evolve, and because of this aspect, more 
impairments may have occurred, although full recovery of kidney function was 
noticed.    
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8. CONCLUSIONS  
The following conclusions can be made based on studies I-IV 
1. Plasma NGAL rises over time in nearly all burn patients. It showed a poor 
sensitivity and specificity to AKI and a lower diagnostic value than SCr or 
CysC. NGAL also reacted more slowly to deteriorating kidney function than 
SCr or CysC (I).  
 
2. Plasma NT-proBNP correlated on cumulative infusions, older age and lower 
BMI during the first week after severe burn injury. A great variation in individual 
level was observed, with an even greater variation in patients with AKI. 
However, an association to AKI was not observed (II).    
  
3. Increasing age, TBSA%, rhabdomyolysis and sepsis were risk factors for AKI. 
The probability of AKI increases along with increasing Baux score. The 
probability of death rises rapidly after Baux score 80; the increase is even 
greater in flame burns. The prognosis in major burns is relatively good without 
AKI, but AKI increases the likelihood of death during a hospital stay even in 
minor burns (III).           
  
4. AKI is common in severe burns and is a considerable risk factor for mortality. 
In addition to AKI, increasing age and TBSA% are both major risk factors for 
death. A difference in in-hospital mortality was not seen between patients 
receiving RRT compared to the rest of the AKI patients. No significant 
difference was noticed in mortality between early and late AKI patients (III).
  
5. ABSI, Baux and modified Baux score are fair and equal predictors of mortality 
after severe burn injury. Their diminishing prediction power may be explained 
by improved burn care (III).       
  
6. Risk for long-term impairment of kidney function is low for burn patients 
treated with RRT. Kidney function recovers in most patients before discharge 
from the burn unit. A minority of patients received RRT for a longer period of 
time, but the need for RRT subsided. 
 
7.  Severe AKI may accelerate underlying weakened kidney function to develop 
into CKD, but could not have been confirmed due to a small number of events 
and confounding factors during follow-up this (IV).  
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9. FUTURE ASPECTS 
Plasma NGAL failed to achieve sufficient diagnostic value in primary diagnostics 
compared to SCr or CysC in study I. NGAL rose constantly in nearly all patients 
whether or not they had AKI. This suggests that an extrarenal component exists. The 
nature of the biomarker can be assessed again when laboratory diagnostics are 
capable of distinguishing renal NGAL from blood. More accurate and rapid means to 
establish ongoing AKI are desired to start interventions to avoid the loss of kidney 
function. Hopefully, some means will be available in the future. Currently there are 
no curative means to prevent ongoing AKI, but many therapies are investigated at 
the moment.  
NT-proBNP turned out to be a potential biomarker to evaluate fluid resuscitation. 
Study II, however, showed a great patient-to-patient variation and a difference in 
tolerance to increased blood volume. Further investigations are needed to eliminate 
possible confounding factors and establish whether or not NT-proBNP could be 
utilized to tailor individual fluid resuscitation after severe burn injury. The amount of 
infused fluids is based on objective measurements rather than on a clinical estimate 
in an ideal situation.  
Study III demonstrated AKI as a notable individual risk factor for death during a 
hospital stay after a severe burn injury. These results demand new methods for a 
faster diagnosis of AKI to establish interventions that prevent AKI from progressing 
and to improve the prognosis of burn victims through these means.  
The number of patients staying dependent on RRT after severe burn injury was small 
in study IV. However, patients who are at an increased risk to develop CKD need to 
be recognized, and this risk needs to be mitigated by evidence-based interventions 
to avoid the permanent later loss of kidney function with its adverse outcomes.   
Organizing a multiburn center study would increase the number of subjects 
included and therefore make it possible to reach sufficient statistical power.   
Investigating causality between interventions and AKI would require randomized 
trials and a large number of patients.
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